<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/453DB5AB-8BFE-4E0A-B761-1C39BD880D5D"><gtr:id>453DB5AB-8BFE-4E0A-B761-1C39BD880D5D</gtr:id><gtr:name>Scripps Research Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EAF17943-4FDF-4E08-A8D2-281D7130987C"><gtr:id>EAF17943-4FDF-4E08-A8D2-281D7130987C</gtr:id><gtr:name>Birkbeck, University of London</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A9426E3-7F35-48FC-BD72-3776C8F90A4A"><gtr:id>4A9426E3-7F35-48FC-BD72-3776C8F90A4A</gtr:id><gtr:name>Grants Admin Office</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C1ED9692-B6AE-4778-BF31-AE813E8E4415"><gtr:id>C1ED9692-B6AE-4778-BF31-AE813E8E4415</gtr:id><gtr:name>MRC Prion Unit</gtr:name><gtr:address><gtr:line1>MRC Prion Unit</gtr:line1><gtr:line2>Institute of Neurology</gtr:line2><gtr:line3>Queen Square</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 3BG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1ED9692-B6AE-4778-BF31-AE813E8E4415"><gtr:id>C1ED9692-B6AE-4778-BF31-AE813E8E4415</gtr:id><gtr:name>MRC Prion Unit</gtr:name><gtr:address><gtr:line1>MRC Prion Unit</gtr:line1><gtr:line2>Institute of Neurology</gtr:line2><gtr:line3>Queen Square</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>WC1N 3BG</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/453DB5AB-8BFE-4E0A-B761-1C39BD880D5D"><gtr:id>453DB5AB-8BFE-4E0A-B761-1C39BD880D5D</gtr:id><gtr:name>Scripps Research Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EAF17943-4FDF-4E08-A8D2-281D7130987C"><gtr:id>EAF17943-4FDF-4E08-A8D2-281D7130987C</gtr:id><gtr:name>Birkbeck, University of London</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A9426E3-7F35-48FC-BD72-3776C8F90A4A"><gtr:id>4A9426E3-7F35-48FC-BD72-3776C8F90A4A</gtr:id><gtr:name>Grants Admin Office</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/0E953CEB-E92F-4800-AFDB-D7FB776FE5B5"><gtr:id>0E953CEB-E92F-4800-AFDB-D7FB776FE5B5</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Collinge</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U123192748"><gtr:id>A2D8C064-1D19-46BA-A4DA-82E003812778</gtr:id><gtr:title>Prion kinetics, toxicity and synthesis and its wider relevance</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U123192748</gtr:grantReference><gtr:abstractText>Prions are germs that cause fatal brain diseases like CJD in humans and BSE (mad cow disease) in cattle. Unlike bacteria or viruses they do not carry their own genes but are made up of rogue forms of one of our own proteins, which build up in the brain as clumps. This unique biology, together with risks to public health from BSE and other prion diseases, has focused our attention on understanding how prions multiply and cause damage to brain cells. We think it is not the prions themselves that damage the brain, but rather something else that is produced when prions grow and have proposed a theory which tries to bring together and explain all we know about prions; we are now testing this to see if it holds up. To do this we have developed a new way of measuring prions. This has been done in the past by injecting material into mice. Our new method just uses mouse cells and so completely avoids having to do animal experiments. We have automated the test and it is much quicker, cheaper and more accurate than using mice. We are developing new cells to measure human prions. It is now clear that what we have been studying in prion diseases is of much wider significance as the commoner dementias like Alzheimers also involve build up of rogue proteins and similar mechanisms may be involved. We will study interactions between prion and Alzheimer disease and see if treatments we are developing for CJD might also work in Alzheimers and other diseases.</gtr:abstractText><gtr:technicalSummary>Prions are lethal pathogens of mammals which occur in multiple biological strains, and yet appear devoid of nucleic acid and composed of aggregated conformational isomers of a host-encoded glycoprotein. Their unique biology, allied with the risks to public health posed by prion zoonoses such as BSE, has focused much attention on understanding the molecular basis of prion propagation and pathogenesis. However, it is clear that the underlying molecular mechanisms, involving aggregation of a misfolded host protein, are of much wider significance and, indeed, analogous protein-based inheritance mechanisms are recognised in yeast and fungi. The common neurodegenerative diseases also involve accumulation of misfolded host proteins and parallels, at multiple levels, in particular with Alzheimers disease, are becoming increasingly apparent. Recent advances suggest that prions themselves are not directly neurotoxic, but rather their propagation involves production of toxic species which may be uncoupled from infectivity. We have proposed a general model to encompass these phenomena, centring on the kinetics of prion propagation, and will test this model using various experimental systems. Our development of an automated, high-throughput, culture-based prion bioassay (ASCA) will be applied to study in vivo kinetics of prion propagation in multiple models and relate this to neurotoxicity and clinical onset. We aim to specifically characterise the determinants of chronic carrier states of prion infection. ASCA will also be used in large-scale studies to attempt high-titre prion synthesis from purified components, an approach completely impractical by conventional rodent bioassay, and determine the role of co-factors. The hypothesis that prion neurotoxicity is mediated by oligomeric species will also be directly investigated. We also aim to develop cell lines to efficiently propagate hamster and human prions to allow extension of these studies beyond mouse-adapted scrape strains and to provide rapid assay of vCJD prions. Interactions between prion and Alzheimer pathogenesis will be explored at several levels, and we will investigate the possible wider role of PrPC in neurotoxicity. Molecular reagents we have developed to target PrPC will be used to investigate possible wider therapeutic strategies in neurodegeneration. Our prion models also provide a test bed for investigating generic approaches to protein misfolding diseases.</gtr:technicalSummary><gtr:fund><gtr:end>2017-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>13520735</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Scripps Research Institute</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Infectology and Microbial Sciences</gtr:department><gtr:description>Prion assay</gtr:description><gtr:id>087A4A4F-0EC0-4118-B8A8-925885E9DC19</gtr:id><gtr:impact>Multiple publications as listed in section 1</gtr:impact><gtr:outcomeId>F8A8848CFFE-1</gtr:outcomeId><gtr:partnerContribution>Co-development of prion strain assay</gtr:partnerContribution><gtr:piContribution>Development of sensitive prion assays</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Birkbeck, University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Biological Sciences</gtr:department><gtr:description>Electron microscopy</gtr:description><gtr:id>B3146BFC-84CE-4EBE-BB63-2D7902F491E6</gtr:id><gtr:impact>Multiple publications as listed in section 1</gtr:impact><gtr:outcomeId>7B1673E4C9F-1</gtr:outcomeId><gtr:partnerContribution>Access to electron microscopy</gtr:partnerContribution><gtr:piContribution>Research collaboration on EM of prion proteins</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Harvard Medical School</gtr:department><gtr:description>Studies of effects of Abeta on synaptic plasticity</gtr:description><gtr:id>7521E377-32D0-498E-A162-78EA80361DC4</gtr:id><gtr:impact>Publications as listed</gtr:impact><gtr:outcomeId>Ty5QWu96vtc-1</gtr:outcomeId><gtr:partnerContribution>Research collaboration</gtr:partnerContribution><gtr:piContribution>Research collaboration</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sheffield</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Molecular Biology and Biotechnology</gtr:department><gtr:description>NMR spectroscopy</gtr:description><gtr:id>7CDCB9F8-3E79-4E66-BF1B-87FB12D8B955</gtr:id><gtr:impact>Multiple publications as listed in section 1</gtr:impact><gtr:outcomeId>A53A6DA5D7F-1</gtr:outcomeId><gtr:partnerContribution>Access to NMR facilites</gtr:partnerContribution><gtr:piContribution>Research collaboration on prion proteins</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Medical and Dental Sciences</gtr:department><gtr:description>Neurophysiology of prion disease</gtr:description><gtr:id>EE6B9BFC-4FF5-46A1-9B0F-AF4BDD7FC9BA</gtr:id><gtr:impact>Multiple publications as listed in section 1</gtr:impact><gtr:outcomeId>6E6A68665D4-1</gtr:outcomeId><gtr:partnerContribution>Access to neurophysiology facilites</gtr:partnerContribution><gtr:piContribution>Research project on prion neurophysiology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Trinity College Dublin</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>Studies of effects of Abeta on in vivo synaptic plasticity</gtr:description><gtr:id>6FB9770A-D2B6-4306-9B4B-C4C628B91997</gtr:id><gtr:impact>Multiple publications as listed in section 1</gtr:impact><gtr:outcomeId>LHkmDXV81aU-1</gtr:outcomeId><gtr:partnerContribution>In vivo studies of synpatic plasticity</gtr:partnerContribution><gtr:piContribution>Research collaboration</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Structural studies of amyloid fibrils</gtr:description><gtr:id>37E0EEC8-96A8-4FC0-B292-156A94D03FE9</gtr:id><gtr:impact>Manuscript in preparation</gtr:impact><gtr:outcomeId>KcMytNCAe6Y-1</gtr:outcomeId><gtr:partnerContribution>Solid state NMR</gtr:partnerContribution><gtr:piContribution>Studies of Alzhiemer's abeta fibrils</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>Prion cell biology</gtr:description><gtr:id>C1E7AB9D-2179-4E9C-83A5-5D6593AF1864</gtr:id><gtr:impact>Multiple publications as listed in section 1</gtr:impact><gtr:outcomeId>095D31F900A-1</gtr:outcomeId><gtr:partnerContribution>Consultative support</gtr:partnerContribution><gtr:piContribution>Research studies on role of proteasome in prion biology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Plenary Lecture Prion Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7DFB19A1-971F-4258-9136-6AF9BDC2432C</gtr:id><gtr:impact>Presented Plenary Lecture at International Prion conference in Colorado.</gtr:impact><gtr:outcomeId>56d6ec35580b14.42461207</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press Release for NEJM Kuru Paper (18 November 2009)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5B66E81C-9BB1-4B8F-AF28-C672B340118F</gtr:id><gtr:impact>Press release for the following paper:

Mead S, Whitfield J, Poulter M, Shah P, Uphill J, Campbell T, Al-Doujaily H, Hummerich H, Beck J, Mein C, Verzilli C, Whittaker J, Alpers M, Collinge J. A novel protective prion protein variant co-localises with kuru exposure. N Engl J Med 2009; 361: 2056-65.

Media interest including an interview for the BBC Radio 4 and article in The Times newspaper. Served to increase public awareness of the Unit's work.</gtr:impact><gtr:outcomeId>oWsj3c7kjfW</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Student ssymposium</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>882F262C-12EB-4620-B450-498FDBBE5A7C</gtr:id><gtr:impact>Gave talk entitled &amp;quot;Prion diseases and their wider relevance in neurodegeneration&amp;quot;</gtr:impact><gtr:outcomeId>58c13f2a122f58.13431922</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>696E30BD-67EC-443C-ACFD-41585031B41A</gtr:id><gtr:impact>workshop on healthy eating as part of the Royal Society of Biology's Biology Week</gtr:impact><gtr:outcomeId>58c7da1c4ba128.78598509</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview with Channel 4 News (14 January 2012)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4A766D1E-3B3C-4F9C-ACEB-CAFF11C41D64</gtr:id><gtr:impact>Interview with Channel 4 News regarding the Prion Unit and The National Prion Clinic offering a CJD blood test.

Interview served to raise public awareness of the test</gtr:impact><gtr:outcomeId>H3kJnZgKhUo</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AAN Annual Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ED1FAFAC-4DC4-4DDD-94DE-A7ADB024B513</gtr:id><gtr:impact>Presented talk to Annual Meeting of the American Academy of Neurology &amp;quot;Development of rational therapeutics for prion infection and its relevance to Alzheimer's disease&amp;quot;</gtr:impact><gtr:outcomeId>58c7deea836071.70071053</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press Release for Nature Communications Paper (6 June 2011)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3B986736-9444-4376-BDB5-7D0B32BD2616</gtr:id><gtr:impact>Press release for the following paper:

Freir DB, Nicoll AJ, Klyubin I, Panico S, Mc Donald JM, Risse E, Asante EA, Farrow -MA, Sessions RB, Saibil HR, Clarke AR, Rowan MJ, Walsh DM Collinge J. Interaction between cellular prion protein and toxic A? oligomers can be therapeutically targeted at multiple sites. Nat Commun 2011; 2:336

The release generated interest from national newspapers including: Independent, Telegraph, Mirror and Daily Mail.

The press release generated articles in national newspapers therefor enhancing public awareness of the Unit's work.</gtr:impact><gtr:outcomeId>WFdnYR8tKTG</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview for Daily Telegraph (27 April 2013)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>372D9A09-BC04-41C8-9A3D-E13FCED062F6</gtr:id><gtr:impact>Interview for the Daily Telegraph regarding Human Exposure to BSE and prevalence of CJD. Resulted in a front page news item in the Daily Telegraph.

Prompted further media enquiries increasing public awareness of the issue.</gtr:impact><gtr:outcomeId>PvZuubERi7t</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release for Dementia Chip Paper (20 February 2013)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A42CC38B-84A8-4A37-9CA5-39C8A795C36B</gtr:id><gtr:impact>Press release for the following paper:

Beck J, Pittman A, Adamson G, Campbell T, Kenny J, Houlden H, Rohrer JD, de Silva R, Shoai M, Uphill J, Poulter M, Hardy J, Mummery CJ, Warren JD, Schott JM, Fox NC, Rossor MN, Collinge J, Mead S. Validation of next generation sequencing technologies in genetic diagnosis of dementia. Neurobiol Aging 2013, (published online ahead of print).

Increased media awareness of paper.</gtr:impact><gtr:outcomeId>bAs5LAFRMBD</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited presentation to USA patient group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D0C94FF0-BFD0-438C-BB02-D42FD021DA39</gtr:id><gtr:impact>Invited presentation to USA patient group

N/A</gtr:impact><gtr:outcomeId>9C5BF636C98</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6001D38D-BF6F-4A14-8A29-A8515428DAC1</gtr:id><gtr:impact>Filmed interview re our published article ;A highly specific blood test for vCJD</gtr:impact><gtr:outcomeId>56d6e8a1a1eb12.54640431</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3F2A9B4C-9DB1-4C57-87B5-2D4C73F5D053</gtr:id><gtr:impact>Presented the Science and Society Lecture at the University of Liverpool</gtr:impact><gtr:outcomeId>56d83f4f955e61.90984503</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pannel discussion in front of live audience</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8F5D81AA-DB6B-474C-A51A-626A265B1A36</gtr:id><gtr:impact>As part of the Hayward Gallery exhibition &amp;quot;History is now&amp;quot; the Director took part in a panel discussion and Q&amp;amp;A session on the subject &amp;quot;perfectly safe to eat - what does looking back at the BSE crisis reveal about changes in agricultre, the rural economy and the price of food&amp;quot;</gtr:impact><gtr:outcomeId>56d6e456cc2218.44892819</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview for BBC Newsnight (29 March 2011)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BA003467-8CD8-4A34-9839-11EA83C097C1</gtr:id><gtr:impact>An interview BBC newsnight regarding surgical decontamination and CJD infection. The interview was broadcast as part of a special feature on the issue.

The interview served to raise public awareness of the issues surrounding surgical decontamination.</gtr:impact><gtr:outcomeId>ERqJcKv3GiM</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Key note speaker for CJD Foundation in Washington</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B83D3F45-4E3C-4123-BCD6-835B4A25A1FD</gtr:id><gtr:impact>Talk sparked sparked questions and discussions

Updated patients families on current research</gtr:impact><gtr:outcomeId>545a1be72ddf68.07931312</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>media briefing</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>23079413-D042-4C5F-AEEC-66458F24A170</gtr:id><gtr:impact>Briefed national and international media on our journal article published in Nature - &amp;quot;: Evidence for human transmission of amyloid-[bgr] pathology and cerebral amyloid angiopathy 10.1038/nature15369&amp;quot;</gtr:impact><gtr:outcomeId>56d6eda626bbe3.04443758</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centenary Open Day (20 June 2013)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C179E852-1BF7-48AA-8145-1DC9105DE397</gtr:id><gtr:impact>Approximately 100 members of the public attended the Prion Unit's Centenary Open Day on 20 June 2013. The presentations prompted a series of questions from patient's families regarding the Unit's current research and aims.

The open date resulted in enquiries from the National Media, including a filmed television interview for ITN News.</gtr:impact><gtr:outcomeId>pz9GBNSXaAt</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release for Lancet Blood Test paper (1 February 2011)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CC838560-ED47-40A3-9A1D-8AD7945CF541</gtr:id><gtr:impact>Press release regarding the publication of the following paper: 

Edgeworth JA, Farmer M, Sicilia A, Tavares P, Beck J, Campbell T, Lowe J, Mead S, Rudge P, Collinge J, Jackson GS. Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet 2011; 377:487-93.

The press release generated a wide-range of media interest resulting in articles published in national newspapers and websites including: The Guardian, BBC News, The Telegraph, The Express, The Daily Mail, The Scotsman and The MIrror.

The resulting media coverage served to raise public awareness of the paper and the Unit's work.</gtr:impact><gtr:outcomeId>e2oG5qTtgJU</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presented to CJD Foundation Family Support Group</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DE2610E6-372B-4DB2-9D2E-EA85E0AD760F</gtr:id><gtr:impact>Approx 50 patient family members attended talk.

Patient group feedback indicated heightened knowledge of this disease as a result of presentation.</gtr:impact><gtr:outcomeId>YPvgbeQQqBP</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Prion Unit and NHS National Prion Clinic Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>85129ACF-A627-4CB7-888A-66F91FEEB717</gtr:id><gtr:impact>Detailed presentation on research strategy and update for patients, familes, carers and health professionals with question and answer session, lab tours and informal discussions with research staff and students

Obtaining feedback on our work, communicating our research and services, building good relationships with our patient group</gtr:impact><gtr:outcomeId>1E8B8330168</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>79A8255C-0FEB-444C-8AE4-874DDD312DCC</gtr:id><gtr:impact>Presented lecture at Nobel Minisymposium at the Karolinska Institute entitled &amp;quot;Basis for amyloid toxicity and treatment strategies&amp;quot;</gtr:impact><gtr:outcomeId>56d6e75542cc20.86681807</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>school visit</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>481EC320-CB38-4195-9EA6-32C3D9152C79</gtr:id><gtr:impact>Gave a short talk about what scientists do then helped children demonstrate their science activity to year 6 children - St Mary's ans St John's CE School, Barnet</gtr:impact><gtr:outcomeId>58c7db5499ee90.72207039</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal Society Meeting on kuru - discussion with media</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D70250C6-8B80-46A4-B1DA-569A22075954</gtr:id><gtr:impact>Discussion with representatives of the media about the meeting to celebrate the end of kuru attended by collaborators and those effected by the disease.

Article in &amp;quot;Times&amp;quot; newspaper was published</gtr:impact><gtr:outcomeId>07F2629AB61</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media exposure RE Nature journal article</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0300FE8C-B968-4D7C-AE63-27572C7B8B97</gtr:id><gtr:impact>Interviews with multiple national and international media outlets. Wide reporting, being front page on every national broadsheet and tabloid newspaper as well as TV and radio.</gtr:impact><gtr:outcomeId>56d6ee2a1e3fe4.13307683</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio Interview, Today Programme BBC Radio 4 (3 February 2011)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>76CA8FDB-3CE4-4CE9-AD71-8A512DD1F47F</gtr:id><gtr:impact>Interviewed on the Today programme, BBC Radio 4, about the publication of the Unit's work on a new CJD blood test. The interview, along with a press release, generated a series of articles in national newspapers and websites.

The interview served to increase public awareness of the blood test and CJD prevalence.</gtr:impact><gtr:outcomeId>cQ88mswS2J8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media interest (Comment for Readers Digest article)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7D546E87-3F18-4F74-8A8E-69B1F1776CB8</gtr:id><gtr:impact>Provided comment on human exposure to BSE for an article published in Readers Digest.

Raising awareness of the work undertaken by MRC</gtr:impact><gtr:outcomeId>QfRugk5AMpx</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release for PNAS paper (26 July 2009)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1A519088-B85D-4935-84DD-F7A75A469FD6</gtr:id><gtr:impact>Press release for the following paper:

Edgeworth J, Gros N, Alden J, Joiner S, Wadsworth JDF, Linehan J, Brandner S, Jackson GS, Weissmann C, Collinge J. Spontaneous generation of mammalian prions. Proc Natl Acad Sci U S A. 2010; 107:14402-6.



Increased media awareness including this video http://www.youtube.com/watch?v=eEC8Ifi6cv0 which raises public awareness of Unit's work</gtr:impact><gtr:outcomeId>hc6A9koCnj1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture at Melbourne Brain Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>0A80990E-6AAF-49A6-9B75-14BE01433387</gtr:id><gtr:impact>Lecture entitled;Prion propagation and neurotoxicity their relationship and wider relevance.</gtr:impact><gtr:outcomeId>56d6e4fea5eef7.26880106</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Bioforum</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C598C56E-7ECB-4FD3-82D8-CE1BC3795388</gtr:id><gtr:impact>Bioforum at Shanghai Insstitute of advanced immunochemical studies</gtr:impact><gtr:outcomeId>58c13fbf2d8b40.56402242</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Exhibition at Hayward Gallery</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EFF07DA4-ABAF-4C4A-91B6-8D5CA701D2E2</gtr:id><gtr:impact>We were very closely involved with the Hayward Gallery exhibition &amp;quot;History is now&amp;quot;. The Unit provided a number of exhibits relating to the BSE crisis. The exhibition ran from 10 February 2015 to 26 April 2015 and attracted large audiences daily.</gtr:impact><gtr:outcomeId>56d6de455d3624.55917408</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview for BBC Radio 4 Today (19 November 2009)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5701390F-3AE0-4911-BFDB-2C7BEB5CE458</gtr:id><gtr:impact>Interview for Today, BBC Radio 4, regarding the publication of the following paper

Mead S, Whitfield J, Poulter M, Shah P, Uphill J, Campbell T, Al-Doujaily H, Hummerich H, Beck J, Mein C, Verzilli C, Whittaker J, Alpers M, Collinge J. A novel protective prion protein variant co-localises with kuru exposure. N Engl J Med 2009; 361: 2056-65.

The interview, along with a press release, generated significant media interest including articles in national newspapers such as the Times

Interview and increased media interest serve to widen public awareness of the Unit's work.</gtr:impact><gtr:outcomeId>JTwoXLcboBe</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description> Parliamentary Select Committee on vCJD prevelance</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>05919996-28AB-4019-BDA5-B1A4D0E46D14</gtr:id><gtr:impact>Report submitted to Department of Health

Awaiting outcome</gtr:impact><gtr:outcomeId>5458a6bccb3a57.40188467</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Member of special panel during CJD Support Network (Australia)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D2A8794B-2877-4959-BB4A-6FBC0D20F0EC</gtr:id><gtr:impact>Served as panel member on special session entitled 'Patient Care, Diagnostics, Genetic CJD and Treatment Trails'. Discussions were conducted in front of an audience of 130 patients and family members

Patient group feedback indicated heightened knowledge of this disease as a result of workshop</gtr:impact><gtr:outcomeId>NamoMuPDT6X</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview with Daily Mail (1 November 2011)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>74467194-ECB2-446D-9F7B-8F4A45FAB8D8</gtr:id><gtr:impact>Interview with the Daily Mail on infectious prions and blood donors. Resulted in an article being published in a National Newspaper.

The interview served to raise public awareness of the issue of Prion disease carriers and blood donations.</gtr:impact><gtr:outcomeId>RxuCbRbc6pB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview with Sky News (3 February 2011)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4505A42E-B6A1-48AC-953F-62C0F84AA999</gtr:id><gtr:impact>Interview with Sky News regarding the Unit's CJD Blood Test.

Interview raised public awareness of the blood test and the Unit's work.</gtr:impact><gtr:outcomeId>amqnecAr2MM</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Plenary Lecture - Magdeline College</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>563EE154-D86C-4D95-A38E-FBBC491FFBE1</gtr:id><gtr:impact>plenary lecture at NECTAR meeting - Magdalene College Cambridge</gtr:impact><gtr:outcomeId>58c14054705355.25120281</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>298096</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The Wolfson Foundation: Leonard Wolfson Experimental Neurology Centre (LWENC) - Blood Biomarkers Theme</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>The Wolfson Foundation</gtr:fundingOrg><gtr:id>F5AB591D-91B6-4BBF-9030-458A8620033C</gtr:id><gtr:outcomeId>tp9k6hfkWfR</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The invention relates to the use of an agent such as an antibody capable of reacting with PrP in the prevention of prion replication in a subject, in th e treatment or prevention of prion infection, in the treatment or prevention o f neuropathology associated with prion infection or in the preparation of a medicament for the treatment or prevention of prion disease. Furthermore, th e invention relates to methods of treatment of prion disease, methods of inhibiting prion replication and antibodies for use in such methods.</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>310FD047-DD0D-44A7-B8F2-C6AC16188C2E</gtr:id><gtr:impact>To follow</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>eqv9v5h2Ujt</gtr:outcomeId><gtr:patentId>CA2507055</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Treatment of prion-induced diseases by administration of anti-prion antibodies</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A novel enzymatic method for prion decontamination and novel assay method for prions bound to metal surfaces.</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>CA228080-01F0-4CEC-9AB4-F2399438F266</gtr:id><gtr:impact>Has been successfully translated and is now manufactured as a CE marked product by the DuPont Corporation: Rely-On PI.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>D5F8E9951FC</gtr:outcomeId><gtr:patentId>WO2008057293?</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Methods and compositions for prion decontamination</gtr:title><gtr:yearProtectionGranted>2006</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention relates to the use of an agent such as an antibody capable of reacting with PrP in the prevention of prion replication in a subject, in the treatment or prevention of prion infection, in the treatment or prevention of neuropathology associated with prion infection or in the preparation of a medicament for the treatment or prevention of prion disease. Furthermore, the invention relates to methods of treatment of prion disease, methods of inhibiting prion replication and antibodies for use in such methods.</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>352C9E5E-26AD-49EA-AC9E-ED18B231E3D5</gtr:id><gtr:impact>To follow</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>tJgeNTxQUGA</gtr:outcomeId><gtr:patentId>WO2004050120</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Treatment of prion-induced diseases by administration of anti-prion antibodies</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Ligands that bind to helix-1 of the prion protein can block the binding of oligomeric amyloid beta peptide and prevent toxicity.</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>6CD49373-3534-4DB8-AE8F-7E5176A486F0</gtr:id><gtr:impact>Nil</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>NG8kfQGDDt3</gtr:outcomeId><gtr:patentId>GB1108490.2</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Methods for Uses (PrP Helix 1 epitope for AD)</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a method for prion decontamination comprising (i) contacting an entity to be contaminated with detergent, (ii) contacting said entity with one or more proteases, and optionally (iii) autoclaving said entity. The detergent may be sodium dodecylsulfate (SDS), and the proteases are selected from a group consisting of ProteinaseK, papain, pronase, and bromelain. The method is directed to the cleaning of surgical instruments and in particular to the removal of the prion agents responsible for vCJD from said medical equipment. The invention further relates to kits comprising detergents and proteases, and compositions comprising proteases and detergents.</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>8528193B-98E4-4DFD-81CE-00227E91A10B</gtr:id><gtr:impact>To follow</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>dUpU9EkhfmQ</gtr:outcomeId><gtr:patentId>GB2394663</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Prion decontamination</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention relates to the use of an agent such as an antibody capable of reacting with PrP in the prevention of prion replication in a subject, in the treatment or prevention of prion infection, in the treatment or prevention of neuropathology associated with prion infection or in the preparation of a medicament for the treatment or prevention of prion disease. Furthermore, the invention relates to methods of treatment of prion disease, methods of inhibiting prion replication and antibodies for use in such methods.</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>D261976B-C2CF-40D9-8672-D4BE639FB241</gtr:id><gtr:impact>To follow</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>FdZGt3NwZDU</gtr:outcomeId><gtr:patentId>EP1565213</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Treatment of prion-induced diseases by administration of anti-prion antibodies</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A method of making a soluble -form of a prion protein which has more -sheet than a -helix structure, can exist as a monomer and retain solubility in an aqueous solution without a denaturant. The method comprises providing a reduced form of the prion protein which does not include a disulphide bond and causing the conformation of the protein to change so that it adopts the -form. Alternatively a method for obtaining a non-aggregated -form of the protein from a sample by partial proteinase K digestion is disclosed. The use of the -form of the protein in medicine, including raising antibodies is disclosed. Methods of screening for compounds capable of inhibiting or reversing the conversion of prion proteins to the -form and the use of these compounds in medicine is also disclosed.; A method of making a soluble -form of a prion protein which has more -sheet than . a. -helix structure, can exist as a monomer and retain solubility in an aqueous solution without a denaturant. The method comprises providing a reduced form of the prion protein which does not include a disulphide bond and causing the conformation of the protein to change so that it adopts the -form. Alternatively a method for obtaining a non-aggregated -form of the protein from a sample by partial proteinase K digestion is disclosed. The use of the -form of the protein in medicine, including raising antibodies is disclosed. Methods of screening for compounds capable of inhibiting or reversing the conversion of prion proteins to the -form and the use of these compounds in medicine is also disclosed.</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>E27E189C-4FF6-477F-BDAD-6A0E3D86B8F5</gtr:id><gtr:impact>To follow</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>gvQzuGoa6Vt</gtr:outcomeId><gtr:patentId>GB2348203</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Soluble beta-forms of prion proteins, methods of preparation and use</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a method for typing a sample of a prion or spongiform encephalopathy disease, a kit suitable for use in such a typing method, a method for identifying infection in an animal and/or tissue of bovine spongiform encephalopathy (BSE), a method for assessing and/or predicting the susceptibility of an animal to BSE, a kit for use in such an assessment and/or prediction method, a method for the treatment of a prion disease, and compounds suitable for such a method.</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>DAAEC7CE-203C-4CA2-8405-8EACD3B46E76</gtr:id><gtr:impact>To follow</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>gi7j47PqFF1</gtr:outcomeId><gtr:patentId>US6998231</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Typing and diagnosis of spongiform encephalopathy</gtr:title><gtr:yearProtectionGranted>2006</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A blood test for the diagnosis of prion disease</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>8C9750B4-2861-4801-9371-45A5FEB5DF8E</gtr:id><gtr:impact>This test is part of an ongoing service evaluation at University College London Hospitals NHS Trust.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>MtsLxzgSg8x</gtr:outcomeId><gtr:patentId>GB1015569</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Assay for Prions</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a method for typing a sample of a prion or spongiform encephalopathy disease, a kit suitable for use in such a typing method, a method for identifying infection in an animal and/or tissue of bovine spongiform encephalopathy (BSE), a method for assessing and/or predicting the susceptibility of an animal to BSE, a kit for use in such an assessment and/or prediction method, a method for the treatment of a prion disease, compounds suitable for such a method, use of such compounds and pharmaceutical agents comprising such compounds.</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>C7DBFEAF-27E0-44AB-89E8-96E448CB4071</gtr:id><gtr:impact>To follow</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>QnVK98PPnh6</gtr:outcomeId><gtr:patentId>EP0934531</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Diagnosis of spongiform encephalopathy</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention relates to compositions and methods for prion degradation, decontamination or disinfection. The composition comprises an oxidizing agent, one or more proteases and a surfactant such as an ionic surfactant/detergent. The method comprises contacting a prion contaminated entity with a prion-degrading composition comprising an effective amount of an oxidizing agent, an effective amount of at least one protease, and an effective amount of a surfactant. The components of the composition may be contacted with a prion-contaminated entity sequentially or simultaneously using an aqueous composition. Typically at least two different proteases are used for optimal efficacy. Preferably the oxidizing agent comprises peracetyl ions or a source thereof. The invention also relates to kits comprising the various reagents.</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>FF4C3B72-32A6-4162-B7D5-3DA5C1EA36F8</gtr:id><gtr:impact>To follow</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>f9e5izVw7Vn</gtr:outcomeId><gtr:patentId>US2011311510</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Compositions and methods for prion decontamination</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a method of making a beta-form of a prion protein which preferably has more beta-sheet than alpha-helix structure and is soluble in the absence of a denaturant and/or is non-aggregated and exhibits partial resistance to digestion with proteinase K. The invention also relates to use of the beta-form in medicine, especially for raising antibodies useful in the treatment and/or diagnosis of prion diseases. The invention also relates to methods of screening for compounds which are capable of inhibiting and/or reversing the conversion of the native alpha-form of a prion protein to a beta-form, and to uses of identified compounds in medicine.</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>37212981-0CBE-493F-B3CD-1C3CF53AE48C</gtr:id><gtr:impact>To follow</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>te3CybZFpAx</gtr:outcomeId><gtr:patentId>US6534036</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Biological materials and methods useful in the diagnosis and treatment of diseases</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a method of making a beta -form of a prion protein which preferably has more beta -sheet than alpha -helix structure and is soluble in the absence of a denaturant and/or is non-aggregated and exhibits partial resistance to digestion with proteinase K. The invention also relates to use of the beta -form in medicine, especially for raising antibodies useful in the treatment and/or diagnosis of prion diseases. The invention also relates to methods of screening for compounds which are capable of inhibiting and/or reversing the conversion of the native alpha -form of a prion protein to a beta -form, and to uses of identified compounds in medicine.

Also relevant:
EP 1127069
US 6534036
US 7875259</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>486D96F5-8349-412C-AD80-D7484A816D18</gtr:id><gtr:impact>To follow</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>BMrZv4JzJdB</gtr:outcomeId><gtr:patentId>WO0026238</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Biological materials and methods useful in the diagnosis and treatment of diseases</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention relates to the use of an agent such as an antibody capable of reacting with PrP in the prevention of prion replication in a subject, in the treatment or prevention of prion infection, in the treatment or prevention of neuropathology associated with prion infection or in the preparation of a medicament for the treatment or prevention of prion disease. Furthermore, the invention relates to methods of treatment of prion disease, methods of inhibiting prion replication and antibodies for use in such methods.

Also relevant:
AU 2003288404 
CA2507055
EP 1565213</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>3BF99B40-E42B-433E-83AC-3872C1C2C8E9</gtr:id><gtr:impact>To follow:</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>maWjDf4uKLQ</gtr:outcomeId><gtr:patentId>US2006280745</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Prion inhibition</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a method of making a beta-form of a prion protein which preferably has more beta-sheet than alpha-helix structure and is soluble in the absence of a denaturant and/or is non-aggregated and exhibits partial resistance to digestion with proteinase K. The invention also relates to use of the beta-form in medicine, especially for raising to antibodies useful in the treatment and/or diagnosis of prion diseases. The invention also relates to methods of screening for compounds which are capable of inhibiting and/or reversing the conversion of the native alpha-form of a prion protein to a beta-form, and to uses of identified compounds in medicine.</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>917C6C3A-0C23-4B1B-A57E-EA0FE401D524</gtr:id><gtr:impact>To follow</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>st3ES7v4Cdv</gtr:outcomeId><gtr:patentId>US 7875259</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Biological materials and methods useful in the diagnosis and treatment of diseases</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention relates to compositions and methods for prion degradation, decontamination or disinfection. The composition comprises an oxidizing agent, one or more proteases and a surfactant such as an ionic surfactant/detergent. The method comprises contacting a prion contaminated entity with a prion-degrading composition comprising an effective amount of an oxidizing agent, an effective amount of at least one protease, and an effective amount of a surfactant. The components of the composition may be contacted with a prion-contaminated entity sequentially or simultaneously using an aqueous composition. Typically at least two different proteases are used for optimal efficacy. Preferably the oxidizing agent comprises peracetyl ions or a source thereof. The invention also relates to kits comprising the various reagents.</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>65E7573A-A23C-436B-8968-52077EDB1B3F</gtr:id><gtr:impact>To follow</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>C9DbudkAvVY</gtr:outcomeId><gtr:patentId>EP2089065</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Methods and compositions for prion decontamination</gtr:title><gtr:yearProtectionGranted>2006</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a method of making a b -form of a prion protein which preferably has more b -sheet than a -helix structure and is soluble in the absence of a denaturant and/or is non-aggregated and exhibits partial resistance to digestion with proteinase K. The invention also relates to use of the b -form in medicine, especially for raising antibodies useful in the treatment and/or diagnosis of prion diseases. The invention also relates to methods of screening for compounds which are capable of inhibiting and/or reversing the conversion of the native a -form of a prion protein to a b -form, and to uses of identified compounds in medicine.; The present invention relates to a method of making a . b. -form of a prion protein which preferably has more . b. -sheet than . a. -helix structure and is soluble in the absence of a denaturant and/or is non-aggregated and exhibits partial resistance to digestion with proteinase K. The invention also relates to use of the . b. -form in medicine, especially for raising antibodies useful in the treatment and/or diagnosis of prion diseases. The invention also relates to methods of screening for compounds which are capable of inhibiting and/or reversing the conversion of the native . a. -form of a prion protein to a . b. -form, and to uses of identified compounds in medicine.</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>C8E77110-E942-4BEA-B016-B2995B081A97</gtr:id><gtr:impact>To follow</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>Lw7fSaSHom6</gtr:outcomeId><gtr:patentId>GB 2371049</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Methods of making antibodies against Beta-forms of prion proteins and their uses</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a method for typing a sample of a prion or spongiform encephalopathy disease, a kit suitable for use in such a typing method, a method for identifying infection in an animal and/or tissue of bovine spongiform encephalopathy (BSE), a method for assessing and/or predicting the susceptibility of an animal to BSE, a kit for use in such an assessment and/or prediction method, a method for the treatment of a prion disease, compounds suitable for such a method, use of such compounds and phamaceutical agents comprising such compounds. 

Also relevant:
US 6,998,231 
EP 0934531</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>D1C4D049-7CBA-4EC4-9B84-9CB3075B6949</gtr:id><gtr:impact>To follow</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>noN1fPsrja4</gtr:outcomeId><gtr:patentId>GB2333362</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Diagnosis of spongiform encephalopathy</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a method of making a b -form of a prion protein which preferably has more b -sheet than a -helix structure and is soluble in the absence of a denaturant and/or is non-aggregated and exhibits partial resistance to digestion with proteinase K. The invention also relates to use of the b -form in medicine, especially for raising antibodies useful in the treatment and/or diagnosis of prion diseases. The invention also relates to methods of screening for compounds which are capable of inhibiting and/or reversing the conversion of the native a -form of a prion protein to a b -form, and to uses of identified compounds in medicine.; The present invention relates to a method of making a . b. -form of a prion protein which preferably has more . b. -sheet than . a. -helix structure and is soluble in the absence of a denaturant and/or is non-aggregated and exhibits partial resistance to digestion with proteinase K. The invention also relates to use of the . b. -form in medicine, especially for raising antibodies useful in the treatment and/or diagnosis of prion diseases. The invention also relates to methods of screening for compounds which are capable of inhibiting and/or reversing the conversion of the native . a. -form of a prion protein to a . b. -form, and to uses of identified compounds in medicine.</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>DC33E802-65CA-407D-8A6C-270380139858</gtr:id><gtr:impact>To follow</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>goc2AAkzsWD</gtr:outcomeId><gtr:patentId>GB2362385</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Non-aggregated beta forms of prion proteins and antibodies against such proteins</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The present invention relates to a method of making a beta -form of a prion protein which preferably has more beta -sheet than alpha -helix structure and is soluble in the absence of a denaturant and/or is non-aggregated and exhibits partial resistance to digestion with proteinase K. The invention also relates to use of the beta -form in medicine, especially for raising antibodies useful in the treatment and/or diagnosis of prion diseases. The invention also relates to methods of screening for compounds which are capable of inhibiting and/or reversing the conversion of the native alpha -form of a prion protein to a beta -form, and to uses of identified compounds in medicine.</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>F0C5FEBF-CBE8-47B1-AE3F-2DBE2131193B</gtr:id><gtr:impact>To follow</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>qwaWoniP5bg</gtr:outcomeId><gtr:patentId>EP1127069</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Method of making a monomeric Beta-form of a prion protein</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention relates to compositions and methods for prion degradation, decontamination or disinfection. The composition comprises an oxidizing agent, one or more proteases and a surfactant such as an ionic surfactant/detergent. The method comprises contacting a prion contaminated entity with a prion-degrading composition comprising an effective amount of an oxidizing agent, an effective amount of at least one protease, and an effective amount of a surfactant. The components of the composition may be contacted with a prion-contaminated entity sequentially or simultaneously using an aqueous composition. Typically at least two different proteases are used for optimal efficacy. Preferably the oxidizing agent comprises peracetyl ions or a source thereof. The invention also relates to kits comprising the various reagents.

Also relevant:
US 2011311510 
EP 2089065</gtr:description><gtr:grantRef>MC_U123192748</gtr:grantRef><gtr:id>BD898CEE-90EC-438A-AFE7-A9713503EB6B</gtr:id><gtr:impact>To follow</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>FuC9aFcX8XE</gtr:outcomeId><gtr:patentId>US2008206843</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Compositions and methods for prion decontamination</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Briefing to PUS for Health re current CJD research</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1DBA9C09-466B-40EC-A291-54477CC72773</gtr:id><gtr:outcomeId>Qh7qN8oBtR9</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Meeting with MP</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0EACC9A4-E3E2-4787-9D42-A7029122484A</gtr:id><gtr:outcomeId>56d84c5e803de6.21926371</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Briefing to PUS for Health &amp;amp; CMO on vCJD research</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A5FF0F84-7B46-430E-87F5-F054DB984AF6</gtr:id><gtr:outcomeId>nQshRdz4Y5g</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Parliamentary Select Committee</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D2CE0620-352E-46E6-935C-ABCBCB70C075</gtr:id><gtr:outcomeId>5458a86a508f70.24429538</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>This is an immunotherapeutic monoclonal antibody developed for the treatment of sporadic CJD. Funded to date by the MRC.</gtr:description><gtr:id>3554F90C-B7F4-4A31-99D3-5419B397E3EE</gtr:id><gtr:impact>To early to say.</gtr:impact><gtr:outcomeId>qw9mWHQqBsr</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Development of PRN100</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>A novel enzymatic method for prion decontamination and novel assay method for prions bound to metal surfaces.</gtr:description><gtr:id>77DD2D3D-C228-4378-9CD7-61AD158E3292</gtr:id><gtr:impact>Various</gtr:impact><gtr:outcomeId>gNRygXYZEfH</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>Decontamination of Surgical Instruments</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:yearDevCompleted>2006</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>A screening test that enables precise detection of vCJD infection.</gtr:description><gtr:id>091E6A06-1854-4DEC-9574-F7BAD23E3B12</gtr:id><gtr:impact>A screening test that enables precise detection of vCJD infection.</gtr:impact><gtr:outcomeId>Y24yUUZXtFk</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Blood Test for vCJD</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>D-Gen Limited</gtr:companyName><gtr:description>D-Gen Limited, an academic spin-out company working in the field of prion disease diagnosis, decontamination, and therapeutics.</gtr:description><gtr:id>0BC44C7E-EE09-4CC7-9F9B-BC292E82427B</gtr:id><gtr:impact>Nil</gtr:impact><gtr:outcomeId>5459f85258e815.01477707</gtr:outcomeId><gtr:yearCompanyFormed>2004</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>ED57ABF3-3211-449C-B13D-E3F20FA0ECB3</gtr:id><gtr:title>A role of cellular prion protein in programming T-cell cytokine responses in disease.</gtr:title><gtr:parentPublicationTitle>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c35e3d09ec2e2e40fe521134fc0b066"><gtr:id>5c35e3d09ec2e2e40fe521134fc0b066</gtr:id><gtr:otherNames>Ingram RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0892-6638</gtr:issn><gtr:outcomeId>QqjpXFTUQwF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3EFFB9A-B919-435F-9EE5-37A68B51CD82</gtr:id><gtr:title>Detection and characterization of proteinase K-sensitive disease-related prion protein with thermolysin.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/53740aa86cab452a475ba97e3f46e1b0"><gtr:id>53740aa86cab452a475ba97e3f46e1b0</gtr:id><gtr:otherNames>Cronier S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>dq7r9BFyTsv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2D1D1A0-6EF1-4CCE-9EFF-8681BEA381D0</gtr:id><gtr:title>Highly sensitive, quantitative cell-based assay for prions adsorbed to solid surfaces.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d7b7e2fe78d5e2742820eea3aa14ddd"><gtr:id>5d7b7e2fe78d5e2742820eea3aa14ddd</gtr:id><gtr:otherNames>Edgeworth JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>KMw8Wd8iXqP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BEC1D0C4-5EB5-4700-BB95-52ADA76C70EE</gtr:id><gtr:title>Central and peripheral pathology of kuru: pathological analysis of a recent case and comparison with other forms of human prion disease.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/124a2925167cbee690b074d32a622cc8"><gtr:id>124a2925167cbee690b074d32a622cc8</gtr:id><gtr:otherNames>Brandner S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>gX37F69iAHF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14C84713-0EA5-4C7E-930F-8591E70D1AFA</gtr:id><gtr:title>Preclinical detection of infectivity and disease-specific PrP in blood throughout the incubation period of prion disease.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55f56b55a8edaec06737db2514e2fe96"><gtr:id>55f56b55a8edaec06737db2514e2fe96</gtr:id><gtr:otherNames>Sawyer EB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56d5aae51177c1.93487536</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>190FBA4D-0011-42D3-85E9-3A1BDEEA3808</gtr:id><gtr:title>Soluble A? aggregates can inhibit prion propagation.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/879894f040f3812d62b2ae898fd16aa4"><gtr:id>879894f040f3812d62b2ae898fd16aa4</gtr:id><gtr:otherNames>Sarell CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>5a9fa6d6072c63.55780722</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31849972-AF89-4269-B0C1-310FA897E8BA</gtr:id><gtr:title>Exosome release from infected dendritic cells: a clue for a fast spread of prions in the periphery?</gtr:title><gtr:parentPublicationTitle>The Journal of infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/545ce42579cf58a78a380cd9bd2cf729"><gtr:id>545ce42579cf58a78a380cd9bd2cf729</gtr:id><gtr:otherNames>Kl?hn PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0163-4453</gtr:issn><gtr:outcomeId>pm_14431_21_23911964</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6619A8BA-BF2E-4F67-8834-5A0D15095A03</gtr:id><gtr:title>Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e65ad8ad8d99155072e5805168e305c6"><gtr:id>e65ad8ad8d99155072e5805168e305c6</gtr:id><gtr:otherNames>Lee SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_14431_21_23193196</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06CB3036-F29D-4782-BCFC-995C67308234</gtr:id><gtr:title>A systematic review of prion therapeutics in experimental models.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f4e6488aef6e1790f01c9944165d070"><gtr:id>6f4e6488aef6e1790f01c9944165d070</gtr:id><gtr:otherNames>Trevitt CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>345F61E41C3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>476D0DAD-A952-40E0-91FE-AF0E2EF2732F</gtr:id><gtr:title>Conformational properties of beta-PrP.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15445b32afbe19ecababb3bb975097f8"><gtr:id>15445b32afbe19ecababb3bb975097f8</gtr:id><gtr:otherNames>Hosszu LL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>V6quFttzqyP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBC6D667-8C6D-48E7-8B5A-712FABD66C36</gtr:id><gtr:title>Threshold for epileptiform activity is elevated in prion knockout mice.</gtr:title><gtr:parentPublicationTitle>Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5052a4ec1bbf8e1f6c3179c4f733ccd6"><gtr:id>5052a4ec1bbf8e1f6c3179c4f733ccd6</gtr:id><gtr:otherNames>Ratt? S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0306-4522</gtr:issn><gtr:outcomeId>azusDcwjntp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C34D0E1B-98FF-4F70-AEF3-6A13B2C71937</gtr:id><gtr:title>Unswitched immunoglobulin M response prolongs mouse survival in prion disease.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe8c83649f29155fd858bc0691162c88"><gtr:id>fe8c83649f29155fd858bc0691162c88</gtr:id><gtr:otherNames>Tayebi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>nFGzeKQJGnE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5005D2B2-5878-4067-97BD-37C3F2CABC1D</gtr:id><gtr:title>No association of PGRN 3'UTR rs5848 in frontotemporal lobar degeneration.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/310bf1b5b3cfcc93127e66670fd761a4"><gtr:id>310bf1b5b3cfcc93127e66670fd761a4</gtr:id><gtr:otherNames>Rollinson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>RojnjjNTqWe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34FE0C45-959E-4853-90CD-FB962921989C</gtr:id><gtr:title>Discrimination between prion-infected and normal blood samples by protein misfolding cyclic amplification.</gtr:title><gtr:parentPublicationTitle>Transfusion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e073b120372c44bd19d0a6219bb4623"><gtr:id>3e073b120372c44bd19d0a6219bb4623</gtr:id><gtr:otherNames>Tattum MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0041-1132</gtr:issn><gtr:outcomeId>pgaEX3kTBKf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C672F51-C986-4B66-8530-C9C306CAF747</gtr:id><gtr:title>Identification of a gene regulatory network associated with prion replication.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97127fedeb24cd2340bd14f53f67f94d"><gtr:id>97127fedeb24cd2340bd14f53f67f94d</gtr:id><gtr:otherNames>Marbiah MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>544fb7aee37a36.51411775</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1CEC0188-D8E8-46EF-984B-9C6D14C08C8B</gtr:id><gtr:title>A novel and rapid method for obtaining high titre intact prion strains from mammalian brain.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f50216d5b995f1fbaf35e380b123fd6c"><gtr:id>f50216d5b995f1fbaf35e380b123fd6c</gtr:id><gtr:otherNames>Wenborn A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56d5aae28b8367.95834050</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDBE2D0B-EB10-4897-9A24-6BF396151519</gtr:id><gtr:title>Crystal structure of human prion protein bound to a therapeutic antibody.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02ad916747b020af716f1fe16ba777e9"><gtr:id>02ad916747b020af716f1fe16ba777e9</gtr:id><gtr:otherNames>Antonyuk SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>S3kHVXzCTgr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>830C6C7D-055E-4C68-BB0E-A73016C6E024</gtr:id><gtr:title>Dissociation of pathological and molecular phenotype of variant Creutzfeldt-Jakob disease in transgenic human prion protein 129 heterozygous mice.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d33325db7c1bbd99fe8b86ca728e230"><gtr:id>6d33325db7c1bbd99fe8b86ca728e230</gtr:id><gtr:otherNames>Asante EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>isodemfoU62</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93ECA518-7336-437F-84B4-668CC233CFB3</gtr:id><gtr:title>Hippocampal bursts caused by changes in NMDA receptor-dependent excitation in a mouse model of variant CJD.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5052a4ec1bbf8e1f6c3179c4f733ccd6"><gtr:id>5052a4ec1bbf8e1f6c3179c4f733ccd6</gtr:id><gtr:otherNames>Ratt? S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>9FA4F823F17</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CB1726F-F716-4CDA-8549-60B91C5950CB</gtr:id><gtr:title>Prion-mediated neurodegeneration is associated with early impairment of the ubiquitin-proteasome system.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72f6f7a612489664bd7da0da0315c636"><gtr:id>72f6f7a612489664bd7da0da0315c636</gtr:id><gtr:otherNames>McKinnon C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>58be6db6655570.06374356</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>393D1822-6C5C-4F43-B868-440F249D8060</gtr:id><gtr:title>The role of ECE1 variants in cognitive ability in old age and Alzheimer's disease risk.</gtr:title><gtr:parentPublicationTitle>American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69c3d9dd16ce35d2096b37dfc9199bc7"><gtr:id>69c3d9dd16ce35d2096b37dfc9199bc7</gtr:id><gtr:otherNames>Hamilton G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1552-4841</gtr:issn><gtr:outcomeId>pm_14431_21_22693153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFD97CEF-128B-451C-AB7A-061E0D69E5D7</gtr:id><gtr:title>Overexpression of the Hspa13 (Stch) gene reduces prion disease incubation time in mice.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e86547207e717145b8a8421a11f93161"><gtr:id>e86547207e717145b8a8421a11f93161</gtr:id><gtr:otherNames>Grizenkova J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_14431_21_22869728</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>573AB073-3900-4CDF-8417-B9A39AAD2B6A</gtr:id><gtr:title>Inherited prion disease with six octapeptide repeat insertional mutation--molecular analysis of phenotypic heterogeneity.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbee40658e79cab5d825627f276ab357"><gtr:id>cbee40658e79cab5d825627f276ab357</gtr:id><gtr:otherNames>Mead S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>CXw2ziH3Yrs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3449E7D-DFD8-4D2C-A740-0C01AC635115</gtr:id><gtr:title>Cardiovascular disease contributes to Alzheimer's disease: evidence from large-scale genome-wide association studies.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0934595a6a2e9c4e4edf812632d6bc4"><gtr:id>e0934595a6a2e9c4e4edf812632d6bc4</gtr:id><gtr:otherNames>Liu G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>544fb7acc48ab8.89865255</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E2068B6-CF42-4430-A3D8-05F78B73A41F</gtr:id><gtr:title>Heterozygosity at polymorphic codon 219 in variant creutzfeldt-jakob disease.</gtr:title><gtr:parentPublicationTitle>Archives of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44154794c63211aac745864409e98d53"><gtr:id>44154794c63211aac745864409e98d53</gtr:id><gtr:otherNames>Lukic A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-9942</gtr:issn><gtr:outcomeId>BnpAo5rqH9m</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C06C0442-ACFE-4615-8F58-19B88797F8D8</gtr:id><gtr:title>Codon 129 polymorphism of the human prion protein influences the kinetics of amyloid formation.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43c07010bfe3a3446b64256aded46ad8"><gtr:id>43c07010bfe3a3446b64256aded46ad8</gtr:id><gtr:otherNames>Lewis PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>JjDakgZeU2e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92A649D0-519F-4914-8F5C-FD7B432D8A1E</gtr:id><gtr:title>Spontaneous generation of mammalian prions.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d7b7e2fe78d5e2742820eea3aa14ddd"><gtr:id>5d7b7e2fe78d5e2742820eea3aa14ddd</gtr:id><gtr:otherNames>Edgeworth JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>SZccVibHkud</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BAC2C84-A089-46FF-ACE7-60EC51B6A2A2</gtr:id><gtr:title>Population Screening for Variant Creutzfeldt-Jakob Disease Using a Novel Blood Test</gtr:title><gtr:parentPublicationTitle>JAMA Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ecb7689760fbf227dccfc9aa9023eede"><gtr:id>ecb7689760fbf227dccfc9aa9023eede</gtr:id><gtr:otherNames>Jackson G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>544fb7adc1d231.04057747</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D192900-5349-4B37-9885-ACC5ECF439D2</gtr:id><gtr:title>Prion propagation and toxicity in vivo occur in two distinct mechanistic phases.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c101120111e9f19df81b4f0bdae6dff"><gtr:id>8c101120111e9f19df81b4f0bdae6dff</gtr:id><gtr:otherNames>Sandberg MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>nfqXJJoyYkQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6612386-579D-4BAA-8912-10FCAAECB0C1</gtr:id><gtr:title>Superoxide dismutase 1 and tgSOD1 mouse spinal cord seed fibrils, suggesting a propagative cell death mechanism in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9ddd65d8294adde2619328d3384b1cd"><gtr:id>f9ddd65d8294adde2619328d3384b1cd</gtr:id><gtr:otherNames>Chia R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>VvUw3gjfgvA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>837ED631-1DEF-4457-A635-7DAA14BE1BCE</gtr:id><gtr:title>Phenotypic heterogeneity and genetic modification of P102L inherited prion disease in an international series.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ecb95f24c0e9454b353263ea6230fa92"><gtr:id>ecb95f24c0e9454b353263ea6230fa92</gtr:id><gtr:otherNames>Webb TE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>HKGWLgMUHoS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36DFCA0C-053F-4500-BA6E-ACBB7FA1D22A</gtr:id><gtr:title>A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72f7fb44cb0e9d3dbae03fa9e859951a"><gtr:id>72f7fb44cb0e9d3dbae03fa9e859951a</gtr:id><gtr:otherNames>Beck J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>a2YMcZhajcJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5643F84E-4EBF-4882-B3DF-E2207B435A57</gtr:id><gtr:title>Early microgliosis precedes neuronal loss and behavioural impairment in mice with a frontotemporal dementia-causing CHMP2B mutation</gtr:title><gtr:parentPublicationTitle>Human Molecular Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71af1acea9b6263e626f005786c1b17e"><gtr:id>71af1acea9b6263e626f005786c1b17e</gtr:id><gtr:otherNames>Clayton E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>58be6db5339f65.22305887</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>951B9358-3E95-4727-848C-F3D8AD22D865</gtr:id><gtr:title>Medicine. Prion strain mutation and selection.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a46902526a5df5054ffa4a1bb4ba33a6"><gtr:id>a46902526a5df5054ffa4a1bb4ba33a6</gtr:id><gtr:otherNames>Collinge J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>rkY71675yQE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>297C462E-F2E6-439F-A2B0-AE6EB3280A89</gtr:id><gtr:title>Pharmacological chaperone for the structured domain of human prion protein.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47d5e240428d904766fabe26c08463fd"><gtr:id>47d5e240428d904766fabe26c08463fd</gtr:id><gtr:otherNames>Nicoll AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>g4WSnPUn161</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>103F5733-7BE5-414B-985C-F1D27483DF13</gtr:id><gtr:title>Beta-PrP form of human prion protein stimulates production of monoclonal antibodies to epitope 91-110 that recognise native PrPSc.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a01d25033815bed5d0d7bc3dc096d32c"><gtr:id>a01d25033815bed5d0d7bc3dc096d32c</gtr:id><gtr:otherNames>Khalili-Shirazi A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>eYvxTyrvudL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>424429A2-3752-469A-BA2D-01F98A1CB2F8</gtr:id><gtr:title>Frontotemporal dementia linked to chromosome 3 (FTD-3)--current concepts and the detection of a previously unknown branch of the Danish FTD-3 family.</gtr:title><gtr:parentPublicationTitle>European journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6466b708f9644403c318702ed53fc9ad"><gtr:id>6466b708f9644403c318702ed53fc9ad</gtr:id><gtr:otherNames>Lindquist SG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1351-5101</gtr:issn><gtr:outcomeId>HT4fB7Xt5DJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E2DAC39-1A40-4F8E-82D9-D5EF7AB68005</gtr:id><gtr:title>A novel presenilin 1 deletion (p.L166del) associated with early onset familial Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>European journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b121c4c0c64cd8e2e7e65f5c4be9911"><gtr:id>0b121c4c0c64cd8e2e7e65f5c4be9911</gtr:id><gtr:otherNames>Knight WD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1351-5101</gtr:issn><gtr:outcomeId>PW3cRuDU55y</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>493F6A64-39EE-4F2C-B419-F8F4152BCB79</gtr:id><gtr:title>Genome-wide association study in multiple human prion diseases suggests genetic risk factors additional to PRNP.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbee40658e79cab5d825627f276ab357"><gtr:id>cbee40658e79cab5d825627f276ab357</gtr:id><gtr:otherNames>Mead S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_14431_21_22210626</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83A0D248-CF9B-4A28-A16A-E4792BD0D00C</gtr:id><gtr:title>HECTD2 is associated with susceptibility to mouse and human prion disease.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aed3a8442858c25b62567496b0f208ac"><gtr:id>aed3a8442858c25b62567496b0f208ac</gtr:id><gtr:otherNames>Lloyd SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>eV3wFAijuUr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F08B91E5-28B0-4046-B2AE-E06A77B370FC</gtr:id><gtr:title>Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1601e9c67e7ea4bd5dad6d3ae17192c"><gtr:id>c1601e9c67e7ea4bd5dad6d3ae17192c</gtr:id><gtr:otherNames>White MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>YNtJnPEcW7f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85D321DD-1918-4A9F-8BB7-A4A85744ADCB</gtr:id><gtr:title>Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9ff70460a8a25a64715383958cc1a82"><gtr:id>a9ff70460a8a25a64715383958cc1a82</gtr:id><gtr:otherNames>Majounie E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>pm_14431_21_22406228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28E04A17-63FA-4592-8AE3-353208BE412F</gtr:id><gtr:title>Age of onset and death in inherited prion disease are heritable.</gtr:title><gtr:parentPublicationTitle>American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ecb95f24c0e9454b353263ea6230fa92"><gtr:id>ecb95f24c0e9454b353263ea6230fa92</gtr:id><gtr:otherNames>Webb TE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1552-4841</gtr:issn><gtr:outcomeId>QMzBSzv3JNE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1418D35-0385-49D2-86C2-9681B72DE41E</gtr:id><gtr:title>Inherited prion disease with 5-OPRI: phenotype modification by repeat length and codon 129.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbee40658e79cab5d825627f276ab357"><gtr:id>cbee40658e79cab5d825627f276ab357</gtr:id><gtr:otherNames>Mead S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>eQMCWdwTh78</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D50C78DA-F048-4E68-8A5C-DCF670B324B6</gtr:id><gtr:title>R47H TREM2 variant increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia.</gtr:title><gtr:parentPublicationTitle>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8cf9d27315b49ef82e560688874a2dd5"><gtr:id>8cf9d27315b49ef82e560688874a2dd5</gtr:id><gtr:otherNames>Slattery CF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1552-5260</gtr:issn><gtr:outcomeId>544fb7b01e1377.71782660</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA3442BC-2C1E-4061-AE6E-3D5DE0B96DC9</gtr:id><gtr:title>Preventing prion pathogenicity by targeting the cellular prion protein.</gtr:title><gtr:parentPublicationTitle>Infectious disorders drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47d5e240428d904766fabe26c08463fd"><gtr:id>47d5e240428d904766fabe26c08463fd</gtr:id><gtr:otherNames>Nicoll AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1871-5265</gtr:issn><gtr:outcomeId>AE467B9861A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7472EFF8-D7A8-4561-ADF1-50A2F30F5A05</gtr:id><gtr:title>Sod1 deficiency reduces incubation time in mouse models of prion disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ae69f09236d5a7d55a0d981da8f5d0e"><gtr:id>0ae69f09236d5a7d55a0d981da8f5d0e</gtr:id><gtr:otherNames>Akhtar S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14431_21_23349894</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E71489CC-F150-4286-B068-DC7092EEDFF7</gtr:id><gtr:title>Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bfddf0327f4fc7ab2fabd5bf3782dae"><gtr:id>8bfddf0327f4fc7ab2fabd5bf3782dae</gtr:id><gtr:otherNames>O'Nuallain B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>Mr2qC8dT7xn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>237E037D-BE31-41B6-B3F4-C0324E415740</gtr:id><gtr:title>Genetic susceptibility, evolution and the kuru epidemic.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbee40658e79cab5d825627f276ab357"><gtr:id>cbee40658e79cab5d825627f276ab357</gtr:id><gtr:otherNames>Mead S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>gZuNBTeFXmU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20FD9A06-B9C1-4D07-A8C3-234A4673CE65</gtr:id><gtr:title>CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96a9bbe73354410988576c36694681de"><gtr:id>96a9bbe73354410988576c36694681de</gtr:id><gtr:otherNames>van der Zee J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>SsKr3n2k2Ke</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>565373AB-85C7-41D4-A919-A39D4A2B1B06</gtr:id><gtr:title>Plasmacytoid dendritic cells sequester high prion titres at early stages of prion infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c97f07ee95a72aa420e52eec7771229f"><gtr:id>c97f07ee95a72aa420e52eec7771229f</gtr:id><gtr:otherNames>Castro-Seoane R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_14431_21_22359509</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08A744AB-ECCE-4CD5-8D57-8BC3356B2396</gtr:id><gtr:title>Linking protective GAB2 variants, increased cortical GAB2 expression and decreased Alzheimer's disease pathology.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f50f494061631e387b397ef9e7255462"><gtr:id>f50f494061631e387b397ef9e7255462</gtr:id><gtr:otherNames>Zou F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14431_21_23724096</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F12D7A87-63BB-460C-BA4A-5508613744E4</gtr:id><gtr:title>Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9da89c318f56fc7256d9d74b60d23229"><gtr:id>9da89c318f56fc7256d9d74b60d23229</gtr:id><gtr:otherNames>Sims R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>5a9fa6d635d1c7.73557093</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D49AD39-CB60-40D5-9452-305A11BAC77C</gtr:id><gtr:title>Prion protein gene M232R variation is probably an uncommon polymorphism rather than a pathogenic mutation.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72f7fb44cb0e9d3dbae03fa9e859951a"><gtr:id>72f7fb44cb0e9d3dbae03fa9e859951a</gtr:id><gtr:otherNames>Beck J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_14431_21_22108575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01B26FFE-5B72-4DDA-A4B5-B302FAAA6DBD</gtr:id><gtr:title>Parietal lobe deficits in frontotemporal lobar degeneration caused by a mutation in the progranulin gene.</gtr:title><gtr:parentPublicationTitle>Archives of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d7991092fd9b17c57c6e7a660ae0f34"><gtr:id>2d7991092fd9b17c57c6e7a660ae0f34</gtr:id><gtr:otherNames>Rohrer JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0003-9942</gtr:issn><gtr:outcomeId>q95GrazrDe5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>981B8880-EBB2-40C1-88AA-CE9ECFC73576</gtr:id><gtr:title>A second family with familial AD and the V717L APP mutation has a later age at onset.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02b2d84c69b20148f1c48c5e0dc75de5"><gtr:id>02b2d84c69b20148f1c48c5e0dc75de5</gtr:id><gtr:otherNames>Godbolt AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>nmGiywFtnVC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>601CB153-D564-407E-8AC5-FAF37BCBC558</gtr:id><gtr:title>Atypical scrapie prions from sheep and lack of disease in transgenic mice overexpressing human prion protein.</gtr:title><gtr:parentPublicationTitle>Emerging infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25db88fcbd041997bffe5354e9a3b87e"><gtr:id>25db88fcbd041997bffe5354e9a3b87e</gtr:id><gtr:otherNames>Wadsworth JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1080-6040</gtr:issn><gtr:outcomeId>pm_14431_21_24188521</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB95C3E3-2D10-4619-9CB4-D7750AAFE63E</gtr:id><gtr:title>Physical, chemical and kinetic factors affecting prion infectivity.</gtr:title><gtr:parentPublicationTitle>Prion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e107587b5118dadea420a7a7c6a23acc"><gtr:id>e107587b5118dadea420a7a7c6a23acc</gtr:id><gtr:otherNames>Properzi F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1933-6896</gtr:issn><gtr:outcomeId>58be6db60b35d7.23990001</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C18B542-0365-42DF-9D1C-5BD854B91187</gtr:id><gtr:title>Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd1ab8c581b76bf8fd748515a9becb00"><gtr:id>dd1ab8c581b76bf8fd748515a9becb00</gtr:id><gtr:otherNames>Wroe SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>r22RvpzA5Gk</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0CCCCF8-E021-4ED6-BC43-78404BA7C5F1</gtr:id><gtr:title>Folding kinetics of the human prion protein probed by temperature jump.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f2112888dab4fb3e6b612aa777ffe44"><gtr:id>1f2112888dab4fb3e6b612aa777ffe44</gtr:id><gtr:otherNames>Hart T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>aguuJBSHEbw</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF7A8BA3-E72C-47D7-9736-FC3FEADA3C25</gtr:id><gtr:title>Brain-water diffusion coefficients reflect the severity of inherited prion disease.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2df16c0b13c37700a2c612d047aa21f4"><gtr:id>2df16c0b13c37700a2c612d047aa21f4</gtr:id><gtr:otherNames>Hyare H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>W5kL5Zce8vo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B468CBC-0B6B-4EE9-9FD8-C3B83F0CF14C</gtr:id><gtr:title>Review: contribution of transgenic models to understanding human prion disease.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25db88fcbd041997bffe5354e9a3b87e"><gtr:id>25db88fcbd041997bffe5354e9a3b87e</gtr:id><gtr:otherNames>Wadsworth JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>VhQgMje5Tp4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3AC944C-6900-4417-A5DC-9E64FC23299C</gtr:id><gtr:title>Association of a null allele of SPRN with variant Creutzfeldt-Jakob disease.</gtr:title><gtr:parentPublicationTitle>Journal of medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cfdf106876171606d0edeedb5461e8f"><gtr:id>5cfdf106876171606d0edeedb5461e8f</gtr:id><gtr:otherNames>Beck JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-2593</gtr:issn><gtr:outcomeId>AwXrfpf5AoH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07BA4339-EB3F-4591-88EB-35CDAFC5EBDC</gtr:id><gtr:title>N-terminal domain of prion protein directs its oligomeric association.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f4e6488aef6e1790f01c9944165d070"><gtr:id>6f4e6488aef6e1790f01c9944165d070</gtr:id><gtr:otherNames>Trevitt CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>544fb7afa6c257.10622533</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21B711C4-AB6D-49FC-8132-933DFEE54230</gtr:id><gtr:title>Methods for Molecular Diagnosis of Human Prion Disease.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6d7fd37105cd0306c02155d831a1698"><gtr:id>c6d7fd37105cd0306c02155d831a1698</gtr:id><gtr:otherNames>Wadsworth JDF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>5a9fa6d6967f15.59022521</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84D2F160-A64B-46D8-9C0A-8500B0FF1EB0</gtr:id><gtr:title>Removal of the glycosylphosphatidylinositol anchor from PrP(Sc) by cathepsin D does not reduce prion infectivity.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43c07010bfe3a3446b64256aded46ad8"><gtr:id>43c07010bfe3a3446b64256aded46ad8</gtr:id><gtr:otherNames>Lewis PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>taiZvQdqbpv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69C7B2E4-86B1-4735-A539-99A3C7D1597B</gtr:id><gtr:title>Targeting glutamatergic and cellular prion protein mechanisms of amyloid ?-mediated persistent synaptic plasticity disruption: Longitudinal studies.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/832216c3df80b3e815bce6a592c6f125"><gtr:id>832216c3df80b3e815bce6a592c6f125</gtr:id><gtr:otherNames>Zhang D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>5a9fa6d6713ad6.90242557</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0CCEBB8-C14C-4C8A-88DC-CC1399609C62</gtr:id><gtr:title>PrP antibodies do not trigger mouse hippocampal neuron apoptosis.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/545ce42579cf58a78a380cd9bd2cf729"><gtr:id>545ce42579cf58a78a380cd9bd2cf729</gtr:id><gtr:otherNames>Kl?hn PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>pm_14431_21_22223800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>958485E9-EA34-4401-931E-035C13FDDE0B</gtr:id><gtr:title>A general model of prion strains and their pathogenicity.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a46902526a5df5054ffa4a1bb4ba33a6"><gtr:id>a46902526a5df5054ffa4a1bb4ba33a6</gtr:id><gtr:otherNames>Collinge J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>SQTRLT2wXbt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B49261EF-0CEB-4E10-862A-84E727B56CAE</gtr:id><gtr:title>Investigation of mcp1 as a quantitative trait gene for prion disease incubation time in mouse.</gtr:title><gtr:parentPublicationTitle>Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2b42af3d965ec21e991e161c0a0cf29"><gtr:id>b2b42af3d965ec21e991e161c0a0cf29</gtr:id><gtr:otherNames>O'Shea M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0016-6731</gtr:issn><gtr:outcomeId>BdXvp2YAQYZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1167ECCE-7625-4BA0-BF80-C026E8213AC4</gtr:id><gtr:title>A reassessment of copper(II) binding in the full-length prion protein.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2b398fefefb405c70b3a85a98965243"><gtr:id>c2b398fefefb405c70b3a85a98965243</gtr:id><gtr:otherNames>Wells MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>GtXywTKNRQd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAFEC9AD-6B28-4361-959E-7444995867DA</gtr:id><gtr:title>Chronic wasting disease prions are not transmissible to transgenic mice overexpressing human prion protein.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c101120111e9f19df81b4f0bdae6dff"><gtr:id>8c101120111e9f19df81b4f0bdae6dff</gtr:id><gtr:otherNames>Sandberg MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>qjHm3SmJnDs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>174F5972-62A7-46C2-BEE2-D6C197A1FD22</gtr:id><gtr:title>Distinct glycoform ratios of protease resistant prion protein associated with PRNP point mutations.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d451a50d5a8944d10f811aa73a12d437"><gtr:id>d451a50d5a8944d10f811aa73a12d437</gtr:id><gtr:otherNames>Hill AF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>sW5Z5uCgCvZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A9EC6A0-C4CC-4BF5-9CD5-4DFDF20E2501</gtr:id><gtr:title>Neuronal antibodies in patients with suspected or confirmed sporadic Creutzfeldt-Jakob disease.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5ee5a13f7d6b0787d4919dd19ba893a"><gtr:id>c5ee5a13f7d6b0787d4919dd19ba893a</gtr:id><gtr:otherNames>Rossi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>544fb7b047e787.82486335</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4009F49-9043-4BEE-B12D-13E9E3C5F29A</gtr:id><gtr:title>Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/738fdd28790b74d120b2b7e362223ce0"><gtr:id>738fdd28790b74d120b2b7e362223ce0</gtr:id><gtr:otherNames>Ghazi-Noori S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_14431_21_22366797</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC516365-E903-4646-AECF-0F21639CBEFD</gtr:id><gtr:title>HECTD2, a candidate susceptibility gene for Alzheimer's disease on 10q.</gtr:title><gtr:parentPublicationTitle>BMC medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aed3a8442858c25b62567496b0f208ac"><gtr:id>aed3a8442858c25b62567496b0f208ac</gtr:id><gtr:otherNames>Lloyd SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1471-2350</gtr:issn><gtr:outcomeId>be4uG27Z2J2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8342DDD0-EC69-4C1E-A97E-4E66B4145BEC</gtr:id><gtr:title>Creutzfeldt-Jakob disease, prion protein gene codon 129VV, and a novel PrPSc type in a young British woman.</gtr:title><gtr:parentPublicationTitle>Archives of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbee40658e79cab5d825627f276ab357"><gtr:id>cbee40658e79cab5d825627f276ab357</gtr:id><gtr:otherNames>Mead S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0003-9942</gtr:issn><gtr:outcomeId>rhaP3YtgaZL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CF26D70-7098-4B50-AAC9-46310CE442DD</gtr:id><gtr:title>TREM2 variants in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56b2d14505f1916bc463c5643c1c28d8"><gtr:id>56b2d14505f1916bc463c5643c1c28d8</gtr:id><gtr:otherNames>Guerreiro R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_14431_21_23150934</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C82C220D-BD86-4334-839E-CE82F218E934</gtr:id><gtr:title>Familial prion disease in a Hungarian family with a novel 144-base pair insertion in the prion protein gene.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c381d26f9875b63e5b1452a990e9005"><gtr:id>8c381d26f9875b63e5b1452a990e9005</gtr:id><gtr:otherNames>Kov?cs T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>EZdSgENkjqB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C6F954F-D504-47B9-B858-2FACFDCF0A56</gtr:id><gtr:title>Functional and genetic analysis of haplotypic sequence variation at the nicastrin genomic locus.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69c3d9dd16ce35d2096b37dfc9199bc7"><gtr:id>69c3d9dd16ce35d2096b37dfc9199bc7</gtr:id><gtr:otherNames>Hamilton G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_14431_21_22405046</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50D7DB45-5512-4DE1-B39A-BF5EF72EC137</gtr:id><gtr:title>Genetic variability in CLU and its association with Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f54cad0ab0877e543fc660186cd44ff0"><gtr:id>f54cad0ab0877e543fc660186cd44ff0</gtr:id><gtr:otherNames>Guerreiro RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>rBXjvZrsjye</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B86331AA-AFAE-4605-B120-63BD74CBEFB4</gtr:id><gtr:title>Disease-associated prion protein oligomers inhibit the 26S proteasome.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b2c9e84a2d8cce8f9ac2c9beec0c386"><gtr:id>0b2c9e84a2d8cce8f9ac2c9beec0c386</gtr:id><gtr:otherNames>Kristiansen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>f62YrE5uKMq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BB2C512-2D2C-4A9B-985B-86A30A54EA64</gtr:id><gtr:title>Cell biology. The risk of prion zoonoses.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a46902526a5df5054ffa4a1bb4ba33a6"><gtr:id>a46902526a5df5054ffa4a1bb4ba33a6</gtr:id><gtr:otherNames>Collinge J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>pm_14431_21_22282797</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A5E921B-38DE-4FA6-893D-9068E6205799</gtr:id><gtr:title>Prion infectivity in variant Creutzfeldt-Jakob disease rectum.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25db88fcbd041997bffe5354e9a3b87e"><gtr:id>25db88fcbd041997bffe5354e9a3b87e</gtr:id><gtr:otherNames>Wadsworth JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>aYnYGz2sZPx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E80CB0AE-0212-469A-B938-E2E751AA1CB0</gtr:id><gtr:title>A highly sensitive immunoassay for the detection of prion-infected material in whole human blood without the use of proteinase K.</gtr:title><gtr:parentPublicationTitle>Transfusion</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e073b120372c44bd19d0a6219bb4623"><gtr:id>3e073b120372c44bd19d0a6219bb4623</gtr:id><gtr:otherNames>Tattum MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0041-1132</gtr:issn><gtr:outcomeId>NrCNsNuUGpN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36EB75A0-5ED0-4040-B831-8D669D370B4E</gtr:id><gtr:title>Lack of TAR-DNA binding protein-43 (TDP-43) pathology in human prion diseases.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8846d6564b676c6cf88dfef4d703f62b"><gtr:id>8846d6564b676c6cf88dfef4d703f62b</gtr:id><gtr:otherNames>Isaacs AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>MFkGsX9WHG3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD26DC8F-8EF6-44DA-A964-2B78E3B5E1CE</gtr:id><gtr:title>Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c101120111e9f19df81b4f0bdae6dff"><gtr:id>8c101120111e9f19df81b4f0bdae6dff</gtr:id><gtr:otherNames>Sandberg MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>544fb7af7a98f9.02983676</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87FE37D1-D15E-4CC0-B0D7-C1255486C1F5</gtr:id><gtr:title>Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72f7fb44cb0e9d3dbae03fa9e859951a"><gtr:id>72f7fb44cb0e9d3dbae03fa9e859951a</gtr:id><gtr:otherNames>Beck J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>pm_14431_21_23434116</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02F2CEBD-5604-4E8D-949A-EAEBB940A0E0</gtr:id><gtr:title>A standardized comparison of commercially available prion decontamination reagents using the Standard Steel-Binding Assay.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d7b7e2fe78d5e2742820eea3aa14ddd"><gtr:id>5d7b7e2fe78d5e2742820eea3aa14ddd</gtr:id><gtr:otherNames>Edgeworth JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>Uhd6eKqVaVV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56A54457-6182-4877-BCC6-AA14CC73C6B1</gtr:id><gtr:title>TMEM106B and ApoE polymorphisms in CHMP2B-mediated frontotemporal dementia (FTD-3).</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4136ca3948d7d31913499a273e1fe367"><gtr:id>4136ca3948d7d31913499a273e1fe367</gtr:id><gtr:otherNames>Rostgaard N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>5a9fa6d5d34e55.38383720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47F4E155-0D9A-4E3C-9C1C-C7B760900094</gtr:id><gtr:title>The H187R mutation of the human prion protein induces conversion of recombinant prion protein to the PrP(Sc)-like form.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15445b32afbe19ecababb3bb975097f8"><gtr:id>15445b32afbe19ecababb3bb975097f8</gtr:id><gtr:otherNames>Hosszu LL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>DA3LtjKKu6P</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F8CC974-CA7F-49D4-A1E5-E78DC6B6E229</gtr:id><gtr:title>A novel protective prion protein variant that colocalizes with kuru exposure.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbee40658e79cab5d825627f276ab357"><gtr:id>cbee40658e79cab5d825627f276ab357</gtr:id><gtr:otherNames>Mead S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>SPyc3DBB3WV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFCEC74A-7A7E-474C-901B-76412AF356D4</gtr:id><gtr:title>Kuru in the 21st century--an acquired human prion disease with very long incubation periods.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a46902526a5df5054ffa4a1bb4ba33a6"><gtr:id>a46902526a5df5054ffa4a1bb4ba33a6</gtr:id><gtr:otherNames>Collinge J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>hnpw7MmsGPK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>162C987E-4ECE-4B0E-AB8D-03E204B152FB</gtr:id><gtr:title>Transmission Properties of Human PrP 102L Prions Challenge the Relevance of Mouse Models of GSS.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d33325db7c1bbd99fe8b86ca728e230"><gtr:id>6d33325db7c1bbd99fe8b86ca728e230</gtr:id><gtr:otherNames>Asante EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>56d5aae3eaf3a5.25992277</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F700274-F9A6-4376-8454-5876DC50C325</gtr:id><gtr:title>A highly specific blood test for vCJD.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d35fcc5cee51bf10673b89f590a94d4a"><gtr:id>d35fcc5cee51bf10673b89f590a94d4a</gtr:id><gtr:otherNames>Jackson GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>544fb7ad2da743.86822306</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AF5513C-18E0-472F-BBCD-FD5DEF28C3F0</gtr:id><gtr:title>Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59ac40b969c64db850e438e12bb3e323"><gtr:id>59ac40b969c64db850e438e12bb3e323</gtr:id><gtr:otherNames>Jones L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>W1RHrunSitc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D8C544D-DC7C-4FA4-9ADE-78F3BB7C3E35</gtr:id><gtr:title>Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29a9c2586c68901d5c8cc3129e94e33d"><gtr:id>29a9c2586c68901d5c8cc3129e94e33d</gtr:id><gtr:otherNames>Schott JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1552-5260</gtr:issn><gtr:outcomeId>58bec774ee4681.22607863</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EFF629A-D53C-4D8C-9268-D818A18C51B0</gtr:id><gtr:title>Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9310cf284c8313db35d3785d3e32077"><gtr:id>a9310cf284c8313db35d3785d3e32077</gtr:id><gtr:otherNames>Harold D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>RCzbdDE8RAh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA55FD1F-66EC-439C-AC1D-87926D96B2DC</gtr:id><gtr:title>A Copine family member, Cpne8, is a candidate quantitative trait gene for prion disease incubation time in mouse.</gtr:title><gtr:parentPublicationTitle>Neurogenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aed3a8442858c25b62567496b0f208ac"><gtr:id>aed3a8442858c25b62567496b0f208ac</gtr:id><gtr:otherNames>Lloyd SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1364-6745</gtr:issn><gtr:outcomeId>iMv5j7huUQa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E1BBF4D2-3E0B-483B-99B3-3C4127FAF9EB</gtr:id><gtr:title>Identification of clinical target areas in the brainstem of prion-infected mice.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b4a14d045add76c8604dba0817e1bf2"><gtr:id>3b4a14d045add76c8604dba0817e1bf2</gtr:id><gtr:otherNames>Mirabile I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>544fb7b0a55050.64269000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DD38AA88-0FC7-4720-A25B-EC8F077C15C2</gtr:id><gtr:title>Absence of spontaneous disease and comparative prion susceptibility of transgenic mice expressing mutant human prion proteins.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d33325db7c1bbd99fe8b86ca728e230"><gtr:id>6d33325db7c1bbd99fe8b86ca728e230</gtr:id><gtr:otherNames>Asante EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>M5mUFp372ug</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D6F9B86-4C15-468B-9636-1991D5DC6042</gtr:id><gtr:title>Inherited prion disease A117V is not simply a proteinopathy but produces prions transmissible to transgenic mice expressing homologous prion protein.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d33325db7c1bbd99fe8b86ca728e230"><gtr:id>6d33325db7c1bbd99fe8b86ca728e230</gtr:id><gtr:otherNames>Asante EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>pm_14431_21_24086135</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B768D2B2-71FD-457A-859E-1578151F11DB</gtr:id><gtr:title>Mammalian prions and their wider relevance in neurodegenerative diseases.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a46902526a5df5054ffa4a1bb4ba33a6"><gtr:id>a46902526a5df5054ffa4a1bb4ba33a6</gtr:id><gtr:otherNames>Collinge J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>58be6db59f41a8.44369821</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>853DB01C-AFF2-4CCA-8B78-AAB4B0B1193C</gtr:id><gtr:title>Inhibition of proteinase K activity by copper(II) ions.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8b3c0d274c9d3ef761e989e7a43f3c0a"><gtr:id>8b3c0d274c9d3ef761e989e7a43f3c0a</gtr:id><gtr:otherNames>Stone LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>SCkAeqpBsqj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9D614BC-77B1-4D20-89DA-9ED412D1C5C7</gtr:id><gtr:title>Successful amplification of degraded DNA for use with high-throughput SNP genotyping platforms.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbee40658e79cab5d825627f276ab357"><gtr:id>cbee40658e79cab5d825627f276ab357</gtr:id><gtr:otherNames>Mead S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>Csufqd7gnqa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A51F1A9C-2FF1-4528-BC33-38A349F481E1</gtr:id><gtr:title>Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbee40658e79cab5d825627f276ab357"><gtr:id>cbee40658e79cab5d825627f276ab357</gtr:id><gtr:otherNames>Mead S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>LxyWYTXJ8XP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB8B3815-805F-47DA-B989-EED5AAC58736</gtr:id><gtr:title>Mapping the progression of progranulin-associated frontotemporal lobar degeneration.</gtr:title><gtr:parentPublicationTitle>Nature clinical practice. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d7991092fd9b17c57c6e7a660ae0f34"><gtr:id>2d7991092fd9b17c57c6e7a660ae0f34</gtr:id><gtr:otherNames>Rohrer JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1745-834X</gtr:issn><gtr:outcomeId>mjnJWpkjWko</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5CD18CC-4616-4891-9983-3418CB4F60A2</gtr:id><gtr:title>Interaction between prion protein and toxic amyloid ? assemblies can be therapeutically targeted at multiple sites.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f87882018fcf76fd424390a5a57f6bed"><gtr:id>f87882018fcf76fd424390a5a57f6bed</gtr:id><gtr:otherNames>Freir DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>BbyAd3YQCxz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4389CDFB-BEE8-46B7-BA3E-F4926E7CEF19</gtr:id><gtr:title>Collinge et al. reply.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a46902526a5df5054ffa4a1bb4ba33a6"><gtr:id>a46902526a5df5054ffa4a1bb4ba33a6</gtr:id><gtr:otherNames>Collinge J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>58bec062404e83.68983255</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10E3C508-3830-4B2B-9675-2483243FAB8D</gtr:id><gtr:title>The human prion protein residue 129 polymorphism lies within a cluster of epitopes for T cell recognition.</gtr:title><gtr:parentPublicationTitle>Journal of neuropathology and experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f2054f5020a7ad7e4cf404fcb230223"><gtr:id>5f2054f5020a7ad7e4cf404fcb230223</gtr:id><gtr:otherNames>Isaacs JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-3069</gtr:issn><gtr:outcomeId>Lk5KCaXeA7t</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D549385A-26C3-465D-90C9-68DA4D195ABE</gtr:id><gtr:title>Alterations in Ca2+-buffering in prion-null mice: association with reduced afterhyperpolarizations in CA1 hippocampal neurons.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b43b18b25faab9ee0e6aaa8dff61fb57"><gtr:id>b43b18b25faab9ee0e6aaa8dff61fb57</gtr:id><gtr:otherNames>Powell AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>6DDFC2E3810</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C92B8B71-3CCC-43B4-B612-4D55983C41D1</gtr:id><gtr:title>ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B).</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84250c2418d270cdf36120ba2a8bc206"><gtr:id>84250c2418d270cdf36120ba2a8bc206</gtr:id><gtr:otherNames>Parkinson N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>VYTo4kzqFcq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69B15F33-5EBB-49FA-A56A-B3E3711E51DC</gtr:id><gtr:title>Amyloid-? nanotubes are associated with prion protein-dependent synaptotoxicity.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47d5e240428d904766fabe26c08463fd"><gtr:id>47d5e240428d904766fabe26c08463fd</gtr:id><gtr:otherNames>Nicoll AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_14431_21_24022506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D41F3BE4-E039-4118-9BE0-5086F96740C8</gtr:id><gtr:title>The cellular prion protein is preferentially expressed by CD4+ CD25+ Foxp3+ regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f2054f5020a7ad7e4cf404fcb230223"><gtr:id>5f2054f5020a7ad7e4cf404fcb230223</gtr:id><gtr:otherNames>Isaacs JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>J4toojrsjkn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0BCB6E0B-9BA2-46F5-A9F2-5B7AAAC31DBC</gtr:id><gtr:title>Frontotemporal dementia and its subtypes: a genome-wide association study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9daf1044ffaa78c220fa83b15b9c753"><gtr:id>b9daf1044ffaa78c220fa83b15b9c753</gtr:id><gtr:otherNames>Ferrari R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1474-4422</gtr:issn><gtr:outcomeId>544fb7af497097.01783882</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77BB723F-28D1-474B-AE84-671BA3C7BA08</gtr:id><gtr:title>Kuru prions and sporadic Creutzfeldt-Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25db88fcbd041997bffe5354e9a3b87e"><gtr:id>25db88fcbd041997bffe5354e9a3b87e</gtr:id><gtr:otherNames>Wadsworth JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>Ehgoc7ZsDoB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84639333-E476-4C83-962D-4B821970EC7A</gtr:id><gtr:title>Experimental sheep BSE prions generate the vCJD phenotype when serially passaged in transgenic mice expressing human prion protein.</gtr:title><gtr:parentPublicationTitle>Journal of the neurological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c6b0f825cf34f269514039fa9fcb879"><gtr:id>2c6b0f825cf34f269514039fa9fcb879</gtr:id><gtr:otherNames>Joiner S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0022-510X</gtr:issn><gtr:outcomeId>5a9fa6d5744f58.95356804</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61CB35B0-698F-438D-ADD1-0CAE338FA0FF</gtr:id><gtr:title>Blood test for variant Creutzfeldt-Jakob disease--reply.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d35fcc5cee51bf10673b89f590a94d4a"><gtr:id>d35fcc5cee51bf10673b89f590a94d4a</gtr:id><gtr:otherNames>Jackson GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>544fb7afd17e40.04917716</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D905FAF-FE39-46FC-8D18-8E6F04B77747</gtr:id><gtr:title>A genome-wide study shows a limited contribution of rare copy number variants to Alzheimer's disease risk.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/028d3b2ceed7be9c07d74b670071bc7f"><gtr:id>028d3b2ceed7be9c07d74b670071bc7f</gtr:id><gtr:otherNames>Chapman J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_14431_21_23148125</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E636AD1-CA82-4083-90FF-927D77585FAC</gtr:id><gtr:title>Rapid cell-surface prion protein conversion revealed using a novel cell system.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b4a39284abbd940f6ef1be5b6468337"><gtr:id>9b4a39284abbd940f6ef1be5b6468337</gtr:id><gtr:otherNames>Goold R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>E3sXABf8u9F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9ED0667D-7DE9-41BB-92B6-C23D43EC3900</gtr:id><gtr:title>Ubiquitin associated protein 1 is a risk factor for frontotemporal lobar degeneration.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/310bf1b5b3cfcc93127e66670fd761a4"><gtr:id>310bf1b5b3cfcc93127e66670fd761a4</gtr:id><gtr:otherNames>Rollinson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>KYL67F9zXsb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3405F7FE-B209-431D-A7E0-979FD6D374DA</gtr:id><gtr:title>Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/35f86b9d72c7d61cef5193d5228058e6"><gtr:id>35f86b9d72c7d61cef5193d5228058e6</gtr:id><gtr:otherNames>Mallucci GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>HGPYvudHosi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>531668A5-1326-4392-BE5D-9F7DFF1162B0</gtr:id><gtr:title>Review. The origin of the prion agent of kuru: molecular and biological strain typing.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25db88fcbd041997bffe5354e9a3b87e"><gtr:id>25db88fcbd041997bffe5354e9a3b87e</gtr:id><gtr:otherNames>Wadsworth JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>MSauh5Z1W7a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1DC319E-20FC-4E2E-82D1-3AB80B594D14</gtr:id><gtr:title>mGlu5 receptors and cellular prion protein mediate amyloid-?-facilitated synaptic long-term depression in vivo.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a19f5e209a9caa48f7577e6439efff3"><gtr:id>1a19f5e209a9caa48f7577e6439efff3</gtr:id><gtr:otherNames>Hu NW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>544fb7adeb92a1.23053803</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF451C53-7BE1-49E1-962C-7F42B53A2DD1</gtr:id><gtr:title>Regional brain metabolite abnormalities in inherited prion disease and asymptomatic gene carriers demonstrated in vivo by quantitative proton magnetic resonance spectroscopy.</gtr:title><gtr:parentPublicationTitle>Neuroradiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba3d675b87e021ae325fde2558b65c5e"><gtr:id>ba3d675b87e021ae325fde2558b65c5e</gtr:id><gtr:otherNames>Waldman AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0028-3940</gtr:issn><gtr:outcomeId>W5gn18bTKZ3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C1BCB50-8EC2-4416-BA39-906CA1345D86</gtr:id><gtr:title>Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dfb50ad82a115894d592e09569cffa3f"><gtr:id>dfb50ad82a115894d592e09569cffa3f</gtr:id><gtr:otherNames>Escott-Price V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544fb7af1aa014.05340403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55A2D1D0-41FB-46D1-988D-1A8F3CBBD15E</gtr:id><gtr:title>Sex effects in mouse prion disease incubation time.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ae69f09236d5a7d55a0d981da8f5d0e"><gtr:id>0ae69f09236d5a7d55a0d981da8f5d0e</gtr:id><gtr:otherNames>Akhtar S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_14431_21_22174884</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5F89BEB-1C8C-4871-8EB0-6589F011B586</gtr:id><gtr:title>In vitro screen of prion disease susceptibility genes using the scrapie cell assay.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e14ad7dc46751cc03b82cf6e81f69dc"><gtr:id>9e14ad7dc46751cc03b82cf6e81f69dc</gtr:id><gtr:otherNames>Brown CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>544fb7aeb539f6.24950396</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF7F9047-1C86-462E-8921-E288B0412ABF</gtr:id><gtr:title>Iatrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01510dcd2c16ce1aeba88470243237a4"><gtr:id>01510dcd2c16ce1aeba88470243237a4</gtr:id><gtr:otherNames>Rudge P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56d5a0123adcd2.56574798</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22A3A923-E065-42C2-B800-D7FBF7E6B7C4</gtr:id><gtr:title>Evidence for human transmission of amyloid-? pathology and cerebral amyloid angiopathy.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46f5fbd4a8def22591a116738bda4515"><gtr:id>46f5fbd4a8def22591a116738bda4515</gtr:id><gtr:otherNames>Jaunmuktane Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>56d5a0e993a294.33407800</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB447AD7-6300-46D8-AC9A-28AA171A5B86</gtr:id><gtr:title>Elongated oligomers assemble into mammalian PrP amyloid fibrils.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e073b120372c44bd19d0a6219bb4623"><gtr:id>3e073b120372c44bd19d0a6219bb4623</gtr:id><gtr:otherNames>Tattum MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>gaVzttrsySE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32FA9D9B-4362-4AE3-A684-4AC6BA27BEBF</gtr:id><gtr:title>Ex vivo mammalian prions are formed of paired double helical prion protein fibrils.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90030108a9bdcf2055469e0536a26b1e"><gtr:id>90030108a9bdcf2055469e0536a26b1e</gtr:id><gtr:otherNames>Terry C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>58be6db62f82d8.30906785</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE3B4737-6BAD-4B9D-9045-2041B17E5670</gtr:id><gtr:title>Shadoo (Sprn) and prion disease incubation time in mice.</gtr:title><gtr:parentPublicationTitle>Mammalian genome : official journal of the International Mammalian Genome Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aed3a8442858c25b62567496b0f208ac"><gtr:id>aed3a8442858c25b62567496b0f208ac</gtr:id><gtr:otherNames>Lloyd SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0938-8990</gtr:issn><gtr:outcomeId>gDBu6eRkesu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C66A876-6D5E-4360-B1C1-A134EE3205B3</gtr:id><gtr:title>Update on human prion disease.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25db88fcbd041997bffe5354e9a3b87e"><gtr:id>25db88fcbd041997bffe5354e9a3b87e</gtr:id><gtr:otherNames>Wadsworth JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>gaJKmN4zyjd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9415B2C-C020-4CAC-B277-24D15D5E98D9</gtr:id><gtr:title>Genetics of prion diseases.</gtr:title><gtr:parentPublicationTitle>Current opinion in genetics &amp; development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aed3a8442858c25b62567496b0f208ac"><gtr:id>aed3a8442858c25b62567496b0f208ac</gtr:id><gtr:otherNames>Lloyd SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0959-437X</gtr:issn><gtr:outcomeId>pm_14431_21_23518043</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8701C8EB-310F-496D-9DA1-C2CE6A72C76C</gtr:id><gtr:title>Novel mutation of the PRNP gene of a clinical CJD case.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a6b5622978dfc916c738ac3b07e43ce2"><gtr:id>a6b5622978dfc916c738ac3b07e43ce2</gtr:id><gtr:otherNames>Kotta K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>sXgdMMsVWD1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C3AC061-4758-400C-8090-81870304A92C</gtr:id><gtr:title>Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS).</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a2c27e62e42f495e188725f3e1be5c4"><gtr:id>9a2c27e62e42f495e188725f3e1be5c4</gtr:id><gtr:otherNames>Shi H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_14431_21_22445811</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F834370-4087-40E2-ACD6-364F7572A1E5</gtr:id><gtr:title>Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d1a7eafc9d349e2e6367fcc16d31c49"><gtr:id>8d1a7eafc9d349e2e6367fcc16d31c49</gtr:id><gtr:otherNames>Fratta P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>pm_14431_21_23818065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>701199B2-EE1B-41A6-91E5-546E5EF1C756</gtr:id><gtr:title>Peripheral administration of a humanized anti-PrP antibody blocks Alzheimer's disease A? synaptotoxicity.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad3e56851fbe594d8926b1dc247e9f57"><gtr:id>ad3e56851fbe594d8926b1dc247e9f57</gtr:id><gtr:otherNames>Klyubin I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>544fb7ae8ba628.60558893</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D427D25D-98D7-4608-8B41-F697E7E6CC55</gtr:id><gtr:title>Collinge et al. reply.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a46902526a5df5054ffa4a1bb4ba33a6"><gtr:id>a46902526a5df5054ffa4a1bb4ba33a6</gtr:id><gtr:otherNames>Collinge J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>58bec061c53f20.09924384</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B5DCCD4-1FE8-40DC-834C-EDAA49DC268D</gtr:id><gtr:title>Introduction.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a46902526a5df5054ffa4a1bb4ba33a6"><gtr:id>a46902526a5df5054ffa4a1bb4ba33a6</gtr:id><gtr:otherNames>Collinge J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>tAbLynWKdwr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3B99860-3A85-467C-B8E4-C70E8A4A0687</gtr:id><gtr:title>Prion protein (PRNP) genotypes in frontotemporal lobar degeneration syndromes.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d7991092fd9b17c57c6e7a660ae0f34"><gtr:id>2d7991092fd9b17c57c6e7a660ae0f34</gtr:id><gtr:otherNames>Rohrer JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>iHcrvCnHv6x</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4F86E2D-EB93-49EF-8AFA-5ADF198635DD</gtr:id><gtr:title>Microglial Cx3cr1 knockout reduces prion disease incubation time in mice.</gtr:title><gtr:parentPublicationTitle>BMC neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e86547207e717145b8a8421a11f93161"><gtr:id>e86547207e717145b8a8421a11f93161</gtr:id><gtr:otherNames>Grizenkova J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2202</gtr:issn><gtr:outcomeId>544fb7ae283664.01930503</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>636068D5-6C82-496E-970E-97BCA6E7DE67</gtr:id><gtr:title>Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab9e3dde384013eef79f476bf114e0e9"><gtr:id>ab9e3dde384013eef79f476bf114e0e9</gtr:id><gtr:otherNames>Urwin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>QLVEceUdnPE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>381733D6-66BD-4A41-A756-5552E2AA17D8</gtr:id><gtr:title>Convergent genetic and expression data implicate immunity in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1229498ce393fd300290a6e5f48128bf"><gtr:id>1229498ce393fd300290a6e5f48128bf</gtr:id><gtr:otherNames>International Genomics of Alzheimer's Disease Consortium (IGAP)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1552-5260</gtr:issn><gtr:outcomeId>56d5aae1816d47.13342867</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D50DBD37-3427-43EF-93BA-2CC43062AB39</gtr:id><gtr:title>Prion Protein as a Toxic Acceptor of Amyloid-? Oligomers.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8275cb03747574d07b4bc0c3bbce5c69"><gtr:id>8275cb03747574d07b4bc0c3bbce5c69</gtr:id><gtr:otherNames>Purro SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>5a9fa6d5a5ccc3.69820687</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58EDB84E-3107-428A-A2DB-DA416173E219</gtr:id><gtr:title>Structural variation in amyloid-? fibrils from Alzheimer's disease clinical subtypes.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ce1bf0af5e48a29032ca4802145231a"><gtr:id>6ce1bf0af5e48a29032ca4802145231a</gtr:id><gtr:otherNames>Qiang W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>58be6db56c4f99.02101081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0551F689-7B2F-4767-9981-56C5129F88FA</gtr:id><gtr:title>A naturally occurring variant of the human prion protein completely prevents prion disease.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d33325db7c1bbd99fe8b86ca728e230"><gtr:id>6d33325db7c1bbd99fe8b86ca728e230</gtr:id><gtr:otherNames>Asante EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>56d5aae3545ce9.38114680</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7582480-FCB6-4785-9404-A85E36683730</gtr:id><gtr:title>A novel Alzheimer disease locus located near the gene encoding tau protein.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e3a671aa40c3ab6ceb98c09b75b6095"><gtr:id>3e3a671aa40c3ab6ceb98c09b75b6095</gtr:id><gtr:otherNames>Jun G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>56d5aae20315b4.16532485</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5BABD9AE-2CAA-4E7F-A992-8DCE235F03D9</gtr:id><gtr:title>Diagnosing Sporadic Creutzfeldt-Jakob Disease by the Detection of Abnormal Prion Protein in Patient Urine.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b20fe581f807c3e4e12bea8541550d02"><gtr:id>b20fe581f807c3e4e12bea8541550d02</gtr:id><gtr:otherNames>Luk C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>58be6db5d64b27.60035632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE790AED-3E18-4855-B47E-F19EC9DFF634</gtr:id><gtr:title>Alternative fates of newly formed PrPSc upon prion conversion on the plasma membrane.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b4a39284abbd940f6ef1be5b6468337"><gtr:id>9b4a39284abbd940f6ef1be5b6468337</gtr:id><gtr:otherNames>Goold R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>pm_14431_21_23813960</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>508D87E6-ACA0-405C-98A9-ADCC5F666238</gtr:id><gtr:title>Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d371ed1fef27a7d68529eead82f76ad7"><gtr:id>d371ed1fef27a7d68529eead82f76ad7</gtr:id><gtr:otherNames>Clayton EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>56d5aae47f5de3.88105580</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3632DD8-4F17-4F91-9318-4341539C7A01</gtr:id><gtr:title>Corticobasal syndrome associated with a novel 1048_1049insG progranulin mutation.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d7991092fd9b17c57c6e7a660ae0f34"><gtr:id>2d7991092fd9b17c57c6e7a660ae0f34</gtr:id><gtr:otherNames>Rohrer JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>Q22aJRk4bNs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74348550-08B8-437F-A9C7-8605AEE9D21E</gtr:id><gtr:title>PRNP allelic series from 19 years of prion protein gene sequencing at the MRC Prion Unit.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cfdf106876171606d0edeedb5461e8f"><gtr:id>5cfdf106876171606d0edeedb5461e8f</gtr:id><gtr:otherNames>Beck JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>aSkVniz56Js</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BEF1406-A88E-469F-833E-4A1EB5DC65A8</gtr:id><gtr:title>Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1db431be05506d4cf0ba9a69ddecabf4"><gtr:id>1db431be05506d4cf0ba9a69ddecabf4</gtr:id><gtr:otherNames>Deriziotis P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>dvRrCrskBYd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD82FCE1-F1C0-424B-A6EA-EE05E4F66EDC</gtr:id><gtr:title>Multiple forms of copper (II) co-ordination occur throughout the disordered N-terminal region of the prion protein at pH 7.4.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c2b398fefefb405c70b3a85a98965243"><gtr:id>c2b398fefefb405c70b3a85a98965243</gtr:id><gtr:otherNames>Wells MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>YBnGQ3CWwHi</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A816DAB7-FBB2-4F3F-B725-F0BB09F69872</gtr:id><gtr:title>Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/028989dcafa83dba91c03e918dc57a1d"><gtr:id>028989dcafa83dba91c03e918dc57a1d</gtr:id><gtr:otherNames>Mahoney CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_14431_21_22366791</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>125D8FBF-D105-4A7B-97EF-9E231F9FED2E</gtr:id><gtr:title>Phenotypic heterogeneity in inherited prion disease (P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25db88fcbd041997bffe5354e9a3b87e"><gtr:id>25db88fcbd041997bffe5354e9a3b87e</gtr:id><gtr:otherNames>Wadsworth JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>AueQMGX8aUn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09817827-BDF8-4572-842F-50B74A507649</gtr:id><gtr:title>No consistent evidence for association between mtDNA variants and Alzheimer disease.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65eb931f142b9d0a96c1e2e4b5b1f6a7"><gtr:id>65eb931f142b9d0a96c1e2e4b5b1f6a7</gtr:id><gtr:otherNames>Hudson G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_14431_21_22442439</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>699E2372-CB69-46FD-9C4E-AB39063795B8</gtr:id><gtr:title>Neuroimaging findings in human prion disease.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a41eab9e924c87f090d69dfaf224b048"><gtr:id>a41eab9e924c87f090d69dfaf224b048</gtr:id><gtr:otherNames>Macfarlane RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>E2gxByZ3Dnx</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>611F6122-2361-4E7E-9C63-E1647B1D7C4D</gtr:id><gtr:title>First report of Creutzfeldt-Jakob disease occurring in 2 siblings unexplained by PRNP mutation.</gtr:title><gtr:parentPublicationTitle>Journal of neuropathology and experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ecb95f24c0e9454b353263ea6230fa92"><gtr:id>ecb95f24c0e9454b353263ea6230fa92</gtr:id><gtr:otherNames>Webb TE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3069</gtr:issn><gtr:outcomeId>NXJTbgFzNA6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7713BAA2-64DA-4F94-B7CA-C4303477B58F</gtr:id><gtr:title>A systematic investigation of production of synthetic prions from recombinant prion protein.</gtr:title><gtr:parentPublicationTitle>Open biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b2740857e0a6a774e56992f6a12381e"><gtr:id>7b2740857e0a6a774e56992f6a12381e</gtr:id><gtr:otherNames>Schmidt C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2046-2441</gtr:issn><gtr:outcomeId>56d5aae4b351e0.54740319</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEF03B87-1B22-4038-8F77-BA6979AFE978</gtr:id><gtr:title>Reminiscences and reflections on kuru, personal and scientific.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a46902526a5df5054ffa4a1bb4ba33a6"><gtr:id>a46902526a5df5054ffa4a1bb4ba33a6</gtr:id><gtr:otherNames>Collinge J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>AQQnk6LryX7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9001E4B4-667E-416D-8036-4E874BE8CDF0</gtr:id><gtr:title>A novel prion disease associated with diarrhea and autonomic neuropathy.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbee40658e79cab5d825627f276ab357"><gtr:id>cbee40658e79cab5d825627f276ab357</gtr:id><gtr:otherNames>Mead S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>544fb7ac87de05.94079714</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44A05034-1BAC-4FD2-9DF0-9D4218FA2041</gtr:id><gtr:title>Quantitative interaction proteomics of neurodegenerative disease proteins.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0f118fe1d7289a14a5998bdd80aaca2"><gtr:id>d0f118fe1d7289a14a5998bdd80aaca2</gtr:id><gtr:otherNames>Hosp F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56d5aae2c6c307.58456342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5E959D1-169C-40AE-8FF5-90810F50578B</gtr:id><gtr:title>Seven-year discordance in age at onset in monozygotic twins with inherited prion disease (P102L).</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc91402d504020448ea53946ad57bcaa"><gtr:id>fc91402d504020448ea53946ad57bcaa</gtr:id><gtr:otherNames>Webb T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>aCHBcJc8SWV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E146270-7C01-432F-9B9D-ADAF8D020D46</gtr:id><gtr:title>Identification of a Compound That Disrupts Binding of Amyloid-? to the Prion Protein Using a Novel Fluorescence-based Assay.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d001463a0fba982a4aca874501488a05"><gtr:id>d001463a0fba982a4aca874501488a05</gtr:id><gtr:otherNames>Risse E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>56d5acd3e4f1e6.94759028</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A161ED6-9F88-4E63-8446-833DDAD8BE52</gtr:id><gtr:title>Molecular pathology of human prion disease.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25db88fcbd041997bffe5354e9a3b87e"><gtr:id>25db88fcbd041997bffe5354e9a3b87e</gtr:id><gtr:otherNames>Wadsworth JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>C54pKR5Fvaf</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U123192748</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>